document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrantgilead sciences inc annual report table content item business item risk factor item unresolved staff comment item property item legal proceeding item safety disclosure item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule item summary signature right trademark copyright trade name business include follow gilead gilead science ambisome axiceltm biktarvy cayston complera descovy emtriva epclusa eviplera genvoya gilead compass initiative harvoni hepsera letairis odefsey ranexa sovaldi stribild synnotch throttle truvada tybost vemlidy viread volibris vosevi yescartatm zydelig atripla register trademark gilead sciences llc lexiscan register trademark astella llc macugen register trademark eyetech inc tamiflu register trademark hoffmannla roche inc report include trademark service mark trade name companiesthis annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forward look statement include statement overall trend operate cost revenue trend liquidity capital need statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forwardlooke statement reason include identify item head risk factor give risk uncertainty caution place undue reliance forwardlooke statement forwardlooke statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forwardlooke statement distribution report result new information future event change assumption item business overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world operation country worldwide headquarters foster city california gileads primary area focus include hivaid liver disease hematologyoncology inflammationrespiratory disease seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy highlight past year continue bring bestinclass drug market advance standard care offering enhance mode delivery convenient treatment regimen improve resistance profile reduce effect great efficacy hiv submit new drug application nda food drug administration fda marketing authorization application maa european medicine agency ema biktarvy oncedaily single tablet regimen contain bictegravir novel investigational integrase strand transfer inhibitor emtricitabine tenofovir alafenamide taf treatment hiv infection adult february receive approval biktarvy united states oncology acquire kite pharma inc kite october shortly receive fda approval yescarta axicabtagene ciloleucel chimeric antigen receptor car cell therapy treatment adult patient relapse refractory large bcell lymphoma line systemic therapy acquisition kite help establish foundation improve treatment hematological malignancy solid tumor liver disease continue advance treatment chronic hepatitis virus hcv infection approval vosevi sofosbuvirvelpatasvirvoxilaprevir single tablet regimen retreatment adult chronic hcv infection sovaldi sofosbuvir treatment chronic hcv infection receive approval china product launch directly china receive european commission approval vemlidy taf oncedaily treatment adult chronic hepatitis virus hbv infection compensate liver disease addition continue advance multiple ongoing clinical study treatment nonalcoholic steatohepatitis nash include evaluation selonsertib ongoing phase study area inflammationrespiratory disease continue advance filgotinib jak inhibitor develop galapagos galapagos ongoing phase clinical trial potential treatment rheumatoid arthritis crohns disease ulcerative colitis end research development pipeline include active clinical study phase clinical trial addition advance treatment option therapeutic area enable access medication people need world continue expand access medicine low middleincome country pursue multiple strategy include enter collaboration government generic manufacturer regional business partner policy maker healthcare provider patient group public health entity today million people receive hiv medicine low middleincome country enter new licensing agreement medicine patent pool mpp united nationsbacke public health organization expand access bictegravir launch gilead compass initiative year million commitment support organization work address hivaid epidemic southern united states hivaid goal ensure hiv patient choose single tablet regiman right single tablet regimen allow patient adhere fully suppressive course therapy easily consistently critical successful management disease hiv patient live long face additional health challenge experience newly diagnose patient motivate continue improve exist treatment option need efficacy improve longterm safety drive development program design study complete plan taf single tablet regimen seek address diverse need hiv patient worldwide taf novel target prodrug tenofovir demonstrate high antiviral efficacy similar dose onetenth viread tenofovir disoproxil fumarate tdf improvement surrogate laboratory marker renal bone safety compare tdf clinical trial combination antiretroviral agent recent approval launch biktarvy united states february single tablet regimen available treatment hiv include taf base single tablet regimen biktarvy genvoya elvitegravircobicistatemtricitabinetaf odefsey emtricitabinerilpivirinetaf expect approval biktarvy european union middle datum phase study evaluate biktarvy treatmentnave patient virologically suppress patient find biktarvy statistically noninferior regimen contain dolutegravir combination dualnrti backbone treatmentnave patient virologically suppress patient biktarvy find statistically noninferior regimen contain boosted protease inhibitor virologically suppress adult patient hiv demonstrate treatmentemergent resistance week continue strong use truvada preexposure prophylaxis prep indication hiv prevention working healthcare community ensure patient provider accurate information appropriate use truvada prep launch targeted medium campaign provide grant community organization raise awareness prep atrisk population education training support demonstration project research effort seek identify optimal implementation strategy prep hiv prevention tool descovy currently evaluate phase clinical trial potential use prep look ahead innovation effort hiv continue research direct new treatment modality pursuit ultimate goal cure liver disease advance treatment option standard care hcv market include provide product meet need hcv patient regardless disease severity genotype prior treatment fda approval sovaldi december compare prior standard care week duration treatment shorten week need peginterferon injection certain viral genotype population reduce eliminate completely harvoni ledipasvirsofosbuvir approve oncedaily single tablet regimen treatment hcv genotype infect patient prevalent genotype united states april fda approve supplemental indication sovaldi harvoni treatment hcv certain pediatric patient epclusa sofosbuvirvelpatasvir approve alloral pangenotypic single tablet regimen treatment adult genotype chronic hcv infection epclusa single tablet regimen approve treatment patient hcv genotype need ribavirin august fda approve expand labeling epclusa include use patient coinfecte hiv july fda european commission approve vosevi oncedaily single tablet regimen retreatment adult hcv offer effective cure patient fail prior therapy highly effective regimen september receive regulatory approval sovaldi china estimate million people estimate live hcv file marketing application vemlidy treatment hbv infection china january receive european commission approval vemlidy oncedaily treatment adult hbv infection compensate liver disease vemlidy approve united states november continue advance ongoing phase study evaluate selonsertib apoptosis signalregulating kinase ask inhibitor treatment nash expect datum available positive form basis regulatory filing october announce phase data result acetylcoa carboxylase acc inhibitor patient nash datum demonstrate lead significant reduction measure liver fat certain biomarker liver fibrosis compare placebo randomize placebocontrolle phase study acc inhibitor nash study suggest potential play important role treat patient disease conduct phase combination study selonsertib selective nonsteroidal fxr agonist patient nash hematologyoncology october complete acquisition kite helped establish leader cellular therapy provide foundation drive continue innovation people advanced cancer kite cell therapy express car engineer cell receptor depend type cancer october yescarta car cell therapy approve fda make car cell therapy treatment adult patient relapse refractory large bcell lymphoma line systemic therapy include diffuse large bcell lymphoma dlbcl specify primary mediastinal bcell lymphoma pmbcl highgrade bcell lymphoma dlbcl arise follicular lymphoma transform follicular lymphoma tfl expect european commission approval yescarta half additional study yescarta indication underway kite additional candidate clinical trial hematologic cancer solid tumor include kite car cell therapy candidate target bcell maturation antigen patient relapsedrefractory multiple myeloma december acquire cell design labs inc cell design labs preclinical stage company significant expertise custom cell engineering company develop proprietary technology platform synnotch synthetic gene expression system respond external cue application deploy engineer car cell require dual antigen recognition activation throttle switch modulate car cell activity small molecule addition technology exist kite research development program lead treatment broad range hematological malignancy solid tumor potentially offer improve selectivity safety future treatment continue advance ongoing phase study andecaliximab mmp mab inhibitor combination mfolfox treatment gastric cancer conduct phase study andecaliximab combination nivolumab versus nivolumab study expect complete quarter inflammationrespiratory disease continue advance ongoing phase clinical trial filgotinib jak inhibitor develop galapago potential treatment rheumatoid arthritis crohns disease ulcerative colitis filgotinib investigate phase study treatment inflammatory disease include psoriatic arthritis ankylose spondylitis lupus sjogren syndrome uveitis product hivaid biktarvy oral formulation dose day treatment hiv infection certain patient biktarvy fixeddose combination antiretroviral medication bictegravir emtricitabine taf descovy oral formulation indicate combination antiretroviral agent treatment hiv infection adult pediatric patient year age old descovy fixeddose combination antiretroviral medication emtricitabine taf odefsey oral formulation dose day treatment hiv infection certain patient odefsey fixeddose combination antiretroviral medication emtricitabine taf rilpivirine hydrochloride market janssen sciences ireland janssen janssen pharmaceutical companies johnson johnson genvoya oral formulation dose day treatment hiv infection adult genvoya single tablet regimen treatment hiv fixeddose combination antiretroviral medicine elvitegravir cobicistat emtricitabine taf stribild elvitegravircobicistatemtricitabinetdf oral formulation dose day treatment hiv infection treatmentnave adult stribild single tablet regimen treatment hiv fixeddose combination antiretroviral medication elvitegravir cobicistat tdf emtricitabine compleraeviplera emtricitabinerilpivirinetdf oral formulation dose day treatment hiv infection adult product market united states complera europe eviplera single tablet regimen treatment hiv fixeddose combination antiretroviral medication tdf emtricitabine janssen rilpivirine atripla efavirenzemtricitabinetdf oral formulation dose day treatment hiv infection adult atripla single tablet regimen hiv intend standalone therapy combination antiretroviral fixeddose combination antiretroviral medication tdf emtricitabine bristolmyers squibb companys bmss efavirenz truvada emtricitabinetdf oral formulation dose day combination therapy treat hiv infection adult fixeddose combination antiretroviral medication tdf emtricitabine fda approve truvada prep indication combination safe sex practice reduce risk sexually acquire hiv infection adult high risk viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection patient year age old european commission approve use viread combination antiretroviral agent treatment hivinfecte adolescent patient age year nucleoside reverse transcriptase inhibitor resistance toxicity precluding use firstline pediatric agent viread approve treatment hbv emtriva oral formulation nucleoside analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult united states europe emtriva available oral solution approve combination therapy treat hiv infection child tybost pharmacokinetic enhancer dose day boost blood level certain hiv medicine tybost indicate boost agent hiv protease inhibitor atazanavir darunavir antiretroviral combination therapy adult hiv infection liver disease vosevi oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir voxilaprevir retreatment hcv infection adult genotype previously treat nsa inhibitorcontaine regiman genotype previously treat sofosbuvircontaine regimen nsa inhibitor vemlidy oral formulation oncedaily treatment taf adult hbv infection compensate liver disease epclusa oral formulation sofosbuvir velpatasvir pangenotypic single tablet regimen treatment adult genotype chronic infection epclusa single tablet regimen approve treatment patient hcv genotype need ribavirin epclusa week approve patient cirrhosis compensate cirrhosis childpugh combination ribavirin patient decompensate cirrhosis childpugh fda approve expand labeling epclusa include use patient infect hiv harvoni oral formulation ledipasvir sofosbuvir dose day treatment genotype hcvhiv coinfection hcv genotype liver transplant recipient genotype infect patient decompensate cirrhosis fda approve supplemental indication harvoni treatment genotype chronic hcv infection adolescent cirrhosis compensate cirrhosis year age older europe harvoni indicate certain patient hcv genotype infection hcv genotype infection cirrhosis andor prior treatment failure hcvhiv coinfection sovaldi oral formulation sofosbuvir dose day treatment hcv component combination antiviral treatment regimen sovaldi efficacy establish patient hcv genotype infection united states europe genotype infection europe include hepatocellular carcinoma meeting milan criterion await liver transplantation hcvhiv infection fda approve supplemental indication sovaldi combination ribavirin treatment genotype chronic hcv infection adolescent cirrhosis compensate cirrhosis year age older viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day treatment hbv adult compensate decompensate liver disease license glaxosmithkline inc gsk right commercialize viread treatment hbv china japan saudi arabia european commission approve use viread treatment hbv infection adolescent patient age year compensate liver disease evidence immune active disease viread approve treatment hiv infection hepsera adefovir dipivoxil oral formulation nucleotide analog polymerase inhibitor dose day treat hbv patient year age old license gsk right commercialize hepsera treatment hbv asia pacific latin america certain territory hematologyoncology yescarta axicabtagene ciloleucel car cell therapy treatment adult patient relapse refractory large bcell lymphoma line systemic therapy include dlbcl specify pmbcl highgrade bcell lymphoma dlbcl arise tfl yescarta currently review ema potential approval expect half zydelig idelalisib firstinclass pik delta inhibitor treatment certain blood cancer united states zydelig approve combination rituximab patient relapse chronic lymphocytic leukemia cll rituximab consider appropriate therapy monotherapy patient relapse follicular bcell nonhodgkin lymphoma small lymphocytic lymphoma receive prior systemic therapy european union zydelig approve treatment cll cardiovascular letairis ambrisentan oral formulation endothelin receptor antagonist indicate treatment pulmonary arterial hypertension pah group patients class iii symptom improve exercise capacity delay clinical worsen sublicense gsk right ambrisentan market gsk volibris ambrisentan pah territory outside united states ranexa ranolazine extendedrelease tablet treatment chronic angina licensed menarini international operation luxembourg rights ranexa territory outside united states lexiscan regadenoson injection indicate use pharmacologic stress agent radionuclide myocardial perfusion imaging test detect characterize coronary artery disease patient unable undergo adequate exercise stress astella llc astella exclusive right manufacture sell regadenoson lexiscan united states rapidscan pharma solutions inc rps hold exclusive right manufacture sell regadenoson rapiscan europe certain territory outside united states receive royalty astella rps sale territory inflammationrespiratory cayston aztreonam inhalation solution inhale antibiotic treatment respiratory system cystic fibrosis patient seven year age old pseudomona aeruginosa aeruginosa tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza tamiflu approve treatment influenza child adult country include united states japan european union tamiflu approve prevention influenza child adults united states japan european union develop tamiflu hoffmannla roche ltd hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay royalty base percentage net sale tamiflu ambisome amphotericin liposome injection proprietary liposomal formulation amphotericin antifungal agent treat invasive fungal infection cause fungal specie adult corporate partner astella pharma inc promote sell ambisome united states canada promote sell ambisome europe australia new zealand macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelate macular degeneration macugen develop eyetech inc eyetech technology license promote united states valeant pharmaceuticals inc valeant acquire eyetech valeant hold exclusive right manufacture sell macugen united states pfizer inc pfizer hold exclusive right manufacture sell macugen rest world receive royalty valeant pfizer base worldwide sale macugen antiviral product sale include sale hiv hbv hcv product billion billion billion respectively represent total revenue total revenue total revenue sale product billion billion billion respectively represent total revenue total revenue total revenue management discussion analysis financial condition result operation include item note segment information note consolidated financial statement include item annual report additional information relate sale product commercialization distribution international commercial sale operation marketing subsidiary country product market commercial team andor conjunction thirdparty distributor corporate partner commercial team promote product direct field contact physician hospital clinic healthcare provider generally grant thirdparty distributor exclusive right promote product territory specify period time agreement distributor provide collaborative effort distributor gilead obtain maintain regulatory approval product specify territory sell distribute product united states exclusively wholesale channel product sale large wholesaler mckesson corporation amerisourcebergen corporation cardinal health inc account total revenue year end december combine basis wholesaler account approximately product sale united states approximately total worldwide revenue sell distribute product europe country outside united states product approve commercial team thirdparty distributor corporate partner patient access priority increase access medicine people benefit regardless ability pay united states patient support program help patient family provide information insurance coverage financial assistance eligibility free medication therapy accessible uninsured individual need financial assistance support program unable afford copayment associate commercial health insurance program half patient take hiv medicine united states receive federal state program substantially discount price long history work state aids drug assistance program adap provide low pricing hiv medicine price freeze institute adap extend end provide important support critical program evolve change healthcare environment corporate giving program aim reduce disparity provide access advance education program support local community example launch gilead compass initiative year million commitment support organization work address hivaid epidemic southern united states develop world access gilead access program establish certain product hivaid viral hepatitis visceral leishmaniasis available substantially reduce price develop world today million people receive hiv medicine low middleincome country enter number collaboration relate access product develop world include license generic manufacturer enter voluntary license agreement generic manufacturers india south africa china allow manufacture generic version hiv hbv product incorporate licensed compound taf cobicistat elvitegravir bictegravir distribution certain low middleincome country enter licensing agreement generic manufacturers india egypt pakistan produce distribute generic version hcv product certain low middleincome country medicine patent pool mpp enter voluntary license agreement mpp united nationsbacke public health organization sublicense right generic manufacturers india china south africa manufacture generic version hiv hbv product incorporate licensed compound taf cobicistat elvitegravir bictegravir distribution certain low middleincome country special partnership work national government local organization increase access hiv hcv medicine strengthen healthcare system recent partnership include partner spouse carribean leader action network sclan address high incidence hiv region elimination mothertochild transmission raise awareness support hiv prevention effort partner organization africa lady hivaids oafla eliminate mothertochild transmission hiv help end aids epidemic continent committed help sclan oafla leader exchange build collaboration maximize synergy region support hcv elimination program arkhangai mongolia donate harvoni treat entire adult population hcv prevalence government arkhangai screen treat adult course month partner government republic georgia centers disease control prevention provide free hcv medicine affect disease country collaborate government healthcare professional country expand health system infrastructure competition market product target number area include hivaid liver disease hematologyoncology inflammationrespiratory cardiovascular disease commercially available product treatment disease face significant competition large global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance ease use price insurance reimbursement coverage distribution marketing product mature private insurer government payer reduce reimburse patient increase pressure reduce price new brand generic product introduce major market ability maintain pricing market share affect hivaid product hiv landscape competitive complex treatment trend continue evolve grow number hiv drug currently market competition current expect competitor erode revenue receive sale hiv product hiv product compete primarily product viiv healthcare company viiv market fixeddose combination product compete biktarvy descovy odefsey genvoya stribild compleraeviplera atripla truvada example product market viiv include tivicay dolutegravir triumeq abacavirdolutegravirlamivudine juluca dolutegravirrilpivirine compete hiv product addition viiv lamivudine compete emtricitabine active pharmaceutical ingredient emtriva component biktarvy descovy odefsey genvoya stribild compleraeviplera atripla truvada tybost compete ritonavir market abbvie inc abbvie hiv product contain taf tdf andor emtrictabine belong nucleoside class antiviral therapeutic treatment paradigm hiv change market share likely decline face competition generic hiv product generic version lamivudine combivir lamivudine zidovudine available united states certain country generic version efavirenz component atripla available united states canada europe observe pricing pressure relate efavirenz component atripla sale addition tdf active pharmaceutical ingredient stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread face generic competition european union united states certain country addition emtricitabine active pharmaceutical ingredient truvada face generic competition european union truvada face generic competition european union certain country outside united states liver disease product continue face competition hcv market hcv product vosevi epclusa harvoni sovaldi compete primarily mavyret glecaprevirpibrentasvir market abbvie zepatier elbasvir grazoprevir market merck inc hcv product revenue decline expect decline result increase competition new hcv product erode net pricing market share expect pricing pressure hcv market continue hbv product vemlidy viread hepsera face competition exist therapy treat patient hbv hbv product face competition generic version tdf hbv product compete baraclude entecavir oral nucleoside analog market bm generic entecavir tyzekasebivo telbivudine oral nucleoside analog market novartis pharmaceutical corporation novartis hematologyoncology product yescarta expect compete company develop advanced cell therapy treatment relapsedrefractory diffuse large bcell lymphoma include novartis product letairis competes tracleer bosentan opsumit macitentan market actelion pharmaceutical inc adcirca tadalafil market united therapeutics corporation pfizer letairis expect face generic competition united states start july ranexa compete predominantly generic compound distinct class drug treatment chronic angina united states include generic andor brand betablocker calcium channel blocker longacte nitrate ranexa expect face generic competition united states start addition number company pursue development technology competitive exist product research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program competitor gain market share result new technology commercialization strategy adversely affect result operation stock price collaborative relationship business strategy establish collaboration company university medical research institution assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company university medical research institution information certain relationship include ongoing financial accounting impact business note collaborative arrangement note consolidated financial statement include item annual report commercial collaboration currently number collaboration corporate partner manufacture sale distribution andor marketing product territory worldwide follow commercial collaboration significant financial statement perspective significant ongoing collaboration activity exist bms north america enter collaboration arrangement bms develop commercialize single tablet regimen contain truvada bmss sustiva efavirenz united states canada combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company consolidate bms grant royaltyfree sublicense joint venture use respective company own technology return grant certain license joint venture use intellectual property result collaboration economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable truvada efavirenz net selling price truvada change time relative net selling price efavirenz bmss respective economic interest joint venture vary annually course collaboration agreement party terminate party participation collaboration day launch generic version party single agent product double agent product terminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination december generic version efavirenz launch united states generic version launch terminate bmss participation collaboration continue party sole owner joint venture december day collaboration result termination transfer gilead bmss ownership interest joint venture consolidate limited liability company whollyowne subsidiary bms long ownership interest joint venture permit commercialize atripla united states canada entitle receive certain royalty net sale atripla calendar year decline annual scale continue purchase efavirenz bm need continue manufacturing atripla united states canada markets europe gilead sciences ireland whollyowne subsidiary bms enter collaboration agreement set forth term condition bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bmss estimate net selling price efavirenz european territory responsible manufacturing product distribution inventory management warehouse local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory bms promote atripla general party share revenue outofpocket expense proportion net selling price component atripla truvada efavirenz start limited number activity jointly manage party long coordinate detail promotional activity european territory responsible accounting financial reporting tax reporting collaboration december efavirenz purchase bms bmss estimate net selling price efavirenz european territory include inventory consolidate balance sheet party form limited liability company hold marketing authorization atripla european territory primary responsibility regulatory activity major market country party agree independently continue use commercially reasonable effort promote atripla agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european territory addition december party terminate agreement reason termination effective calendar quarter notice termination nonterminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination event continue party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early janssen enter license collaboration agreement janssen sciences ireland janssen tibotec pharmaceutical develop commercialize fixeddose combination truvada janssen nonnucleoside reverse transcriptase inhibitor rilpivirine combination approve united states european union sell brand complera united states eviplera european union original agreement janssen grant exclusive license compleraeviplera worldwide exclude certain middle income develop world country japan responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization product country janssen distribute janssen exercise right codetail combination product country gilead sell party party terminate collaboration agreement respect product country product withdraw market country respect product country party materially breach agreement respect product agreement party obligation share revenue expire productbyproduct countrybycountry basis janssen patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement cause respect country sell product case janssen right sell party country product launch market few year japan tobacco japan tobacco inc japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize elvitegravir treatment hiv infection bear cost expense associate commercialization effort receive approval stribild elvitegravircontaine product fda august european commission receive approval genvoya elvitegravircontaine product fda european commission november agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party research collaboration number collaboration partner research development certain compound drug candidate research collaboration significant financial statement perspective research development philosophy strategy develop bestinclass drug improve safety efficacy unmet medical need intend continue commit significant resource internal opportunity external business development activity product development effort cover wide range medical condition include hivaid liver disease hematologyoncology inflammationrespiratory disease research scientist primarily foster city santa monica california seattle washington alberta canada engage discovery development new molecule technology hope lead approval new medicine advance current standard care address unmet medical need development product candidate subject risk uncertaintie risk uncertainty include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain regulatory approval result product candidate successfully commercialize drug development inherently risky product candidate fail drug development process summary key product candidate correspond current stage development product candidate treatment hivaid product candidate description product phase descovy descovy evaluate prep indication product phase tlr agonist evaluate treatment hiv infection broadly neutralize antibody bnab evaluate treatment hiv infection product candidate treatment liver disease product candidate description product phase selonsertib selonsertib ask inhibitor evaluate treatment nash product phase selonsertib selonsertib evaluate treatment alcoholic hepatitis acc inhibitor evaluate treatment nash fxr agonist evaluate treatment nash primary biliary cirrhosis primary sclerose cholangitis product phase tlr agonist evaluate treatment hbv infection product candidate treatment hematologyoncology product candidate description product phase andecaliximab andecaliximab mmp mab inhibitor evaluate treatment gastric cancer axicabtagene ciloleucel axicabtagene ciloleucel evaluate treatment second line diffuse large bcell lymphoma idelalisib idelalisib pik delta inhibitor evaluate treatment relapse refractory chronic lymphocytic leukemia product phase axicabtagene ciloleucel axicabtagene ciloleucel evaluate treatment indolent nonhodgkin lymphoma axicabtagene ciloleucel evaluate treatment diffuse large bcell lymphoma combination anti pdl mab entospletinib entospletinib syk inhibitor evaluate treatment hematological malignancy tirabrutinib tirabrutinib btk inhibitor evaluate treatment bcell malignancy ktec ktec car cell therapy evaluate treatment mantle cell lymphoma product phase andecaliximab andecaliximab evaluate treatment solid tumor bet inhibitor evaluate treatment solid tumor ktec ktec evaluate treatment adult pediatric acute lymphoblastic leukemia kite kite antibcma evaluate treatment multiple myeloma kite kite mage evaluate treatment solid tumor product candidate treatment inflammationrespiratory disease product candidate description product phase filgotinib filgotinib jak inhibitor evaluate treatment rheumatoid arthritis crohns disease ulcerative colitis product phase filgotinib filgotinib evaluate treatment inflammatory disease presatovir presatovir fusion inhibitor evaluate treatment respiratory syncytial virus syk inhibitor evaluate treatment sjogren syndrome lupus product candidate product candidate description product phase nuc inhibitor evaluate treatment ebola virus infection total expense billion billion billion expense decrease compare primarily impact business development activity result upfront collaboration expense relate license collaboration agreement galapago acquire inprocess iprd expense relate purchase nimbus apollo inc nimbus iprd impairment charge ongoing milestone payment partially offset acquire iprd expense relate purchase cell design lab addition internal discovery clinical development program seek add portfolio product product acquisition license collaboration acquire kite shortly receive fda approval axicabtagene ciloleucel know commercially yescarta make car cell therapy treatment adult patient relapse refractory large bcell lymphoma line systemic therapy include dlbcl tfl pmbcl expect european commission approval yescarta half additional study yescarta indication underway kite additional candidate clinical trial hematologic cancer solid tumor include kite car cell therapy candidate target bcell maturation antigen patient relapsedrefractory multiple myeloma acquire cell design labs preclinical stage company significant expertise custom cell engineering company develop proprietary technology platform synnotch synthetic gene expression system respond external cue application deploy engineer car cell require dual antigen recognition activation throttle switch modulate car cell activity small molecule addition technology exist kite research development program lead treatment broad range hematological malignancy solid tumor potentially offer improve selectivity safety future treatment patent proprietary right european patent expiration number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states european union primary typically compound patent phase product candidate product candidate single tablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen phase product candidate patent expiration product candidate treatment hiv descovy prep product candidate treatment liver disease selonsertib treatment nash product candidate treatment hematologyoncology andecaliximab treatment gastric cancer axicabtagene ciloleucel treatment second line diffuse large bcell lymphoma idelalisib treatment relapse refractory cll product candidate treatment inflammationrespiratory disease filgotinib treatment rheumatoid arthritis crohns disease ulcerative colitis date parenthesis reflect estimate expiration date patent issue currently pende application estimate expiration date include potential additional exclusivity patent term extension supplementary protection certificate pediatric exclusivity grant composition matter patent expire european union european union united states patent application pende relate kite proprietary manufacturing process follow table show actual estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states european union primary typically compound patent market product patent cover ranolazine active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve product fixeddose combination single tablet regimen truvada atripla compleraeviplera stribild genvoya odefsey descovy biktarvy estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen product patent expiration letairis viread ranexa atripla cayston emtriva truvada lexiscan descovy vemlidy compleraeviplera zydelig odefsey yescarta sovaldi stribild genvoya tybost harvoni epclusa biktarvy vosevi estimate expiration date include potential additional exclusivity patent term extension supplementary protection certificate pediatric exclusivity grant gilead watson laboratories inc reach agreement settle patent litigation relate letairis gilead teva pharmaceutical teva reach agreement principle settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate viread truvada atripla product agreement teva allow launch generic version viread december gilead lupin limited lupin reach agreement settle patent litigation prior issuance court decision agreement lupin allow launch generic version ranexa february gilead teva reach agreement settle patent litigation concern patent protect emtricitabine truvada atripla product supplementary protection certificate spc grant european country validity spc challenge generic manufacturer launch conpete product validity spc consider national court court justice european union composition matter patent expire european union european union united states patent application pende relate kite proprietary manufacturing process application patent term extension pende united states andor spc pende country european union product application patent term extension file united states grant extend expiration date application spc file european union grant extend expiration date patent protection certain challenge patent proprietary right important business properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology patent cover certain active pharmaceutical ingredient api hiv product yescarta letairis ranexa hold party acquire exclusive right patent agreement party patent cover ranolazine active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level obtain patent formulation characteristic plasma level achieve yescarta composition matter patent expire european union european union united states patent application pende related kite proprietary manufacturing process obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country example extension patent supplementary protection certificate product grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain country important infringe valid patent party infringe valid patent party require pay significant monetary damage prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware patent patent application own party party claim cover use sofosbuvir axicabtagene ciloleucel bictegravir patent application confidential period time patent issue know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate interferencederivation proceeding litigation determine right patent litigation interferencederivation proceeding unpredictable expensive ultimately successful result operation adversely affect event patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation proceeding enforcement validity exist patent future patent result invalidation patent substantially reduce protection time time certain individual entity challenge patent pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product closely relate developed develop addition certain country provide effective enforcement patent thirdparty manufacturer able sell generic version product country description significant pende legal proceeding note commitment contingency legal proceeding note consolidated financial statement include item annual report trade secret rely unpatented trade secret improvement unpatente internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret confidential information know independently discover competitor enter dispute ownership invention business result operation adversely affect manufacture raw material product manufacture facility thirdparty manufacturer corporate partner depend party manufacture majority api solid dose product rely corporate partner manufacture certain product additionally lease manufacturing facility foster city san dimas verne oceanside segundo california edmonton alberta canada cork ireland manufacture certain product api clinical andor commercial use manufacturing product contract party manufacture certain api clinical commercial purpose include vosevi epclusa harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya odefsey descovy biktarvy vemlidy emtriva tybost ranexa ambisome zydelig cayston generally use multiple thirdparty contract manufacturer manufacture api product exclusive manufacturer ambrisentan api letairis supplier qualify api rely thirdparty contract manufacturer manufacture oral liquid tablet capsule product example use multiple thirdparty contract manufacturer manufacture epclusa harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya odefsey descovy biktarvy vemlidy ranexa emtriva vosevi tybost letairis zydelig hepsera complete thirdparty contract manufacturer addition rely thirdparty contract manufacturer manufacture aseptic product ambisome cayston establish clinical commercial manufacturing facility cell processing activity yescarta yescarta car cell therapy involve harvesting cell patient blood engineering cell express cancerspecific receptor iii increase number engineer cell infuse functional cancerspecific cell patient future product continue develop additional manufacturing capability establish additional thirdparty supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale manufacturing facility foster city california facility conduct process chemistry research development activity manufacture api clinical trial oversee thirdparty contract manufacturer san dimas california verne california facilities manufacture ambisome san dimas package label majority commercial product distribute product america pacific rim utilize oceanside california facility clinical manufacture process development biologic candidate preclinical phase phase testing utilize segundo california facility clinical commercial manufacture process yescarta patientbypatient basis utilize cork ireland facility commercial manufacture packaging label antiviral product perform quality control testing labeling package final release product distribution european union international market edmonton alberta facility canada carry process research scaleup clinical development candidate manufacture api investigational commercial product conduct chemical development activity improve exist commercial manufacturing process thirdparty manufacturer thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval writeoff cost manufacturing batch fail pass quality inspection meet regulatory approval extent risk materialize affect performance obligation financial result adversely affect addition thirdparty manufacturer corporate partner able produce product limit number facility limited manufacturing capacity certain product believe technology use manufacture product proprietary product manufacture thirdparty contract manufacturer disclose necessary aspect technology enable manufacture product agreement thirdparty manufacturer intend restrict manufacturer reveal technology certain thirdparty manufacturer comply restriction addition thirdparty manufacturer develop technology relate work perform need manufacture product require enter additional agreement thirdparty manufacturer want use technology allow manufacturer use technology thirdparty manufacturer refuse allow use technology demand term use technology acceptable regulation manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation thirdparty manufacturer corporate partner subject current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard define fda ema similar regulation effect jurisdiction manufacture operation subject routine inspection regulatory agency unable remedy deficiency cite fda inspection currently market product time regulatory approval product development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country yescarta require fda comply risk evaluation mitigation strategy program include educate certify medical personnel therapy procedure potential effect profile therapy potential adverse effect relate cytokine release syndrome neurologic toxicity additionally require maintain complex chain identity custody respect patient material material move manufacturing facility manufacturing process patient access supply material need access certain supply product conduct clinical trial manufacture product unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue example significant portion raw material intermediate manufacture antiviral product supply thirdparty manufacturer corporate partner outside united states result political economic factor specific country region include change interpretation trade regulation compliance requirement tax legislation limit prevent party outside united states supply material adversely affect ability manufacture supply antiviral product meet market need material adverse effect operating result seasonal operation backlog worldwide product sale reflect significant degree seasonality operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states countries united states european union country drug subject rigorous regulation federal state statute regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume regulatory requirement applicable drug development approval subject change legal regulatory change impact operation future country regulatory agency fda united states emaeuropean commission european union approve drug sell respective country country general process drug approval united states summarize country include country european union similar regulatory structure preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept ind drug candidate study human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous phase clinical trial phase drug candidate appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial conduct long term involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial fda approval process believe datum clinical trial acceptable benefitrisk profile submit appropriate filing usually form nda supplemental nda fda seek approval sell drug candidate particular use fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree compound meet require level safety efficacy particular use allow sell drug candidate united states use unusual fda reject application believe drug candidate safe efficacious believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california include segundo verne oceanside san dimas facility license state california compliance local regulatory requirement edmonton alberta manufacturing facility canada facility locate near dublin cork ireland obtain local license permit compliance local regulatory requirement drug treat lifethreatening disease condition adequately address exist drug development program design address unmet medical need designate fast track candidate fda eligible priority review drug treatment hiv infection designate use president emergency plan aid relief qualify expedite priority review rest world drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union include major country europe centralize approval procedure approval country european union obtain approval country european union simplified application process mutual recognition procedure decentralize procedure rely principle mutual recognition receive regulatory approval european registration procedure separate pricing reimbursement approval require country european union requirement approval manufacturing facility product approve sale european regulatory authority price reimbursement successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment market sell product government health authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service significant portion sale majority product subject substantial discount list price addition nonretail sector united states include government institution include state adap department veteran affair correctional facility large health maintenance organization tend consistent term buy pattern cause quarteroverquarter fluctuation necessarily mirror patient demand product federal state budget pressure include sequestration annual grant cycle federal state fund cause purchasing pattern reflect patient demand product example quarter certain prior year observe large nonretail purchase hiv product number state adap exceed patient demand believe purchase drive grant cycle federal adap fund expect continue experience fluctuation purchase pattern nonretail customer result fluctuation product sale revenue earning future light budget crisis face european country observe variation purchase pattern induce cost containment measure europe believe measure cause government agency purchaser reduce inventory product distribution channel decrease revenue cause fluctuation product sale earning continue trend future product mature private insurer government payer reduce reimburse patient increase pressure reduce price new brand generic product introduce major market ability maintain pricing market share affect example tdf active pharmaceutical ingredient stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread face generic competition european union united states certain country addition emtricitabine active pharmaceutical ingredient truvada face generic competition european union truvada face generic competition european union certain country outside united states negative impact business result operation item risk factor substantial portion revenue derive sale product treat hiv hcv unable increase hiv sale hcv sale decrease anticipate result operation adversely affect patient assistance program recently enhance scrutiny companysponsore patient assistance program include insurance premium copay assistance program donation thirdparty charity provide assistance enhance scrutiny government reimbursement support offering clinical education program promotional speaker program agents vendor donation recipient deem fail comply law regulation government guidance area subject criminal civil sanction similar violation competitor negatively impact industry reputation increase scrutiny business product item risk factor law regulation applicable health care industry impose new obligation require change business practice restrict operation future united states healthcare reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction unite states pharmaceutical manufacturer brand drug product require pay portion industry fee know brand prescription drug bpd fee calculate base select government sale year percentage total industry government sale annual bpd fee impose pharmaceutical industry billion billion bpd fee expense million million million bpd fee tax deductible november election president trump congress numerous effort repeal amend affordable care act house representative vote pass american health care act ahca repeal provision affordable care act senate consider fail pass ahca comparable measure congress consider legislation repeal replace element affordable care act addition tax cut job act president trump sign law december repeal affordable care act individual health insurance mandate consider key component affordable care act future stability affordable care act result impact business uncertain material addition state propose legislation seeks indirectly directly regulate pharmaceutical drug pricing require biopharmaceutical manufacturer publicly report proprietary pricing information place maximum price ceiling pharmaceutical product purchase state agency propose legislation pass experience additional pricing pressure product example october californias governor sign prescription drug price transparency state bill law require prescription drug manufacturer provide advance notice explanation price increase certain drug exceed specify threshold similar bill previously introduce federal level expect additional legislation introduce year potential effect health insurance market destabilization ongoing repeal replace discussion impact potential change way medicaid program finance likely affect patient source insurance resultant drug coverage discussion continue federal level policy allow require government directly negotiate drug price pharmaceutical manufacturer medicare patient require manufacturer pay high rebate medicare state flexibility drug cover medicaid program policy proposal impact reimbursement product discussion center legislation permit reimportation prescription medication canada country difficult predict impact legislation executive action medicaid flexibility use reimbursement product united states include potential importation generic version product yescarta administer inpatient basis possible federal government reimbursement program like medicare medicaid insufficient cover complete cost associate therapy impact willingness hospital offer therapy doctor recommend therapy lessen attractiveness therapy patient adverse effect sale yescarta result operation addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule health care fraud abuse law antibribery law subject federal state law pertain health care fraud abuse include antikickback law false claim law antikickback law illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision increase attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law generally prohibit knowingly present cause present false fraudulent claim payment federal certain state payer include medicare medicaid knowingly make cause false record statement material false fraudulent claim sale marketing patient support medical activity subject scrutiny law addition foreign corrupt practice act similar worldwide antibribery law generally prohibit company intermediary make improper payment purpose obtain retain business policy mandate compliance antibribery law operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital state control manner different local custom despite train compliance program internal control policy procedure protect reckless criminal act commit employee agent violation fraud abuse law antibribery law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid violation lead imposition corporate integrity agreement similar government oversight program government allege convict violate law disruption business material adverse effect result operation compulsory license number develop country government official interested group suggest pharmaceutical company drug hiv hcv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example grow attention availability hcv therapy activist advocate increase availability hcv therapy mean include compulsory license government malaysia exercise government right section malaysian patent act practice patent invention sofosbuvir period year use government hospital clinic challenge malaysian government action past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread compulsory license permit generic manufacturing override product patent hiv hcv product require grant compulsory license product reduce earning cash flow harm business addition certain country permit enforcement patent permit patent issue thirdparty manufacturer able sell generic version product country example brazilian health regulatory agency reject patent application relate sofosbuvir hcv product successfully appeal decision application examination brazilian patent trademark office sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale employee january approximately employee believe good relation employee environment health safety strive reduce environmental footprint implement sustainable business process practice incorporate sustainability development distribution medicine safety regulatory compliance product regular efficiency improvement manufacturing process operation surround product portfolio routinely evaluate new innovative way incorporate social environmental responsibility practice include ethical source material green chemistry practice solvent recycling continue improvement sustainability efficiency api product development process gilead site world identify opportunity reduce natural resource usage water conservation sustainable building practice energy conservation recycling diversion landfill alternative transportation continue look way minimize impact environment factor contribute environmental impact include greenhouse gas emission produce employee commute energy water consume facility use hazardous material chemical viruse radioactive compound facility refer year review find website wwwgileadcom responsibility measure take mitigate environmental impact business subject number law regulation require compliance federal state local regulation workplace safety protection environment anticipate additional regulation near future law regulation implement consideration mitigate effect climate change mainly cause greenhouse gas emission business energy intensive anticipate subject cap trade system mitigation measure materially impact capital expenditure operation competitive position base current information subject finalization propose regulation believe primary risk relate climate change increase energy cost information subject information requirement exchange act file periodic report proxy statement information sec report proxy statement information obtain visit public reference room sec street washington call sec sec send electronic message sec publicinfosecgov send fax sec addition sec maintain website wwwsecgov contain report proxy information statement information issuer file electronically mail address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filing section available follow filing soon reasonably practicable electronically file furnished sec annual report quarterly report form current report form amendment report file furnish pursuant section exchange act filing available free charge request transaction iran transaction iran require disclosure annual report item risk factor evaluate business carefully consider follow risk addition information annual report manifestation follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider follow risk complete statement potential risk uncertainty face substantial portion revenue derive sale product treat hiv hcv unable increase hiv sale hcv sale decrease anticipate result operation adversely affect receive substantial portion revenue sale product treatment hiv infection include genvoya truvada atripla descovy stribild odefsey compleraeviplera year end december sale hiv product account approximately total product sale expect hiv product account high percentage total product sale hiv product contain tenofovir alafenamide taf tenofovir disoproxil fumarate tdf andor emtricitabine belong nucleoside class antiviral therapeutic treatment paradigm hiv change cause nucleosidebase therapeutic fall favor unable maintain increase hiv product sale result operation likely suffer likely need scale operation include spend research development effort year end december sales harvoni epclusa sovaldi vosevi treatment hcv account approximately total product sale primary driver hcv product revenue patient start net pricing market share second quarter number new patient start diminish expect patient start continue decline relative major market result decrease hcv product sale hcv revenue decline expect decline result increase competition new hcv product erode net pricing market share anticipate impact pricing market share fully reflect mid hcv product sale impact large anticipate shift payer mix highly discount payer segment geographic region addition future sale hcv product difficult estimate demand depend extent reimbursement hcv product private government payer continue experience global pricing pressure result large discount rebate product delay reimbursement negatively impact product sale result operation private public payer choose exclude hcv product formulary coverage list limit type patient coverage provide negatively impact demand revenue hcv product change formulary coverage reimbursement level discount rebate offer hcv product payer impact anticipate revenue expect pricing pressure hcv market continue unable achieve forecasted hcv sale stock price experience significant volatility unable sustain increase sale hiv hcv product number reason include limited reason discuss follow hiv hcv product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning contraindication label narrow approve indication halt sale product reduce revenue product mature private insurer government payer reduce reimburse patient product increase pressure reduce price physician benefit hiv hcv product sale hiv hcv product limit new branded generic product introduce major market ability maintain pricing market share affect example tdf active pharmaceutical ingredient stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread face generic competition european union united states certain country addition emtricitabine active pharmaceutical ingredient truvada face generic competition european union truvada face generic competition european union certain country outside united states expect continue negative impact business result operation fail commercialize new product expand indication exist product prospect future revenue adversely affect introduce new product increase sale exist product able increase maintain total revenue continue expand effort drug development inherently risky product candidate fail drug development process example terminate phase study treatment rheumatoid arthritis cystic fibrosis phase study treatment hepatitis virus addition decide terminate product development expend significant resource effort addition unable obtain regulatory approval product candidate recent acquisition kite pharma inc kite effectively commercialize kite product candidate able realize anticipate benefit acquisition kite include expect future revenue kite product candidate file marketing authorization application maa european union approval oncedaily single tablet regimen contain bictegravir emtricitabinetenofovir alafenamide treatment hiv infection adult file maa european union approval axicabtagene ciloleucel treatment relapsedrefractory diffuse large bcell lymphoma transform follicular lymphoma primary mediastinal bcell lymphoma future marketing application file approve regulatory authority timely basis marketing approval grant product significant limitation use unable file marketing application new product inability accurately predict demand product uptake new product fluctuation customer inventory make difficult accurately forecast sale cause forecast revenue earning fluctuate adversely affect financial result stock price unable accurately predict demand product include uptake new product demand dependent number factor example nonretail sector united states include government institution include state aids drug assistance program adap department veteran affair correctional facility large health maintenance organization tend consistent term buy pattern cause quarteroverquarter fluctuation necessarily mirror patient demand product federal state budget pressure annual grant cycle federal state fund cause purchasing pattern reflect patient demand product example quarter certain prior year observe large nonretail purchase hiv product number state adap exceed patient demand believe purchase drive grant cycle federal adap fund expect continue experience fluctuation purchase pattern nonretail customer result fluctuation product sale revenue earning future light budget crisis face european country observe variation purchase pattern induce cost containment measure europe believe measure cause government agency purchaser reduce inventory product distribution channel decrease revenue cause fluctuation product sale earning continue trend future year end december approximately product sale united states wholesaler mckesson corp amerisourcebergen corp cardinal health inc wholesaler enter inventory management agreement estimate determine end user demand completely effective match inventory level actual end user demand result change inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand addition inventory hold retail pharmacy nonwholesaler location inventory management agreement control buy pattern adverse change economic condition increase competition factor cause retail pharmacy reduce inventory product reduce order wholesaler consequently wholesalers order end user demand change example fourth quarter strong wholesaler subwholesaler purchase product result inventory drawdown wholesaler subwholesaler quarter inventory distribution channel fluctuate quarter quarter continue fluctuation earning mismatch prescription demand product revenue hcv product represent cure competitor hcv product enter market revenue hcv product difficult investor estimate primary driver hcv product revenue patient start net pricing market share experience number patient start difficult accurately predict addition demand hcv product depend extent reimbursement hcv product private public payer united states country private public payer choose exclude hcv product formulary coverage list limit type patient coverage provide negatively impact demand revenue hcv product continue experience pricing pressure united states european union country change formulary coverage reimbursement level discount rebate offer hcv product payer negatively impact anticipate revenue addition rebate claim product discount payer quarter arrear estimate rebate require pay connection sale particular quarter base claim datum prior quarter hcvrelate revenue difficult predict investor widely vary expectation materially higher low actual anticipate revenue extent actual anticipate hcv product revenue exceed fall short expectation stock price experience significant volatility yescarta chimeric antigen receptor car cell therapy represent novel approach cancer treatment create significant challenge yescarta car cell therapy involve harvesting cell patient blood engineering cell express cancerspecific receptor iii increase number engineer cell infuse functional cancerspecific cell patient advance novel personalize therapy create significant challenge include educate certify medical personnel procedure potential effect profile therapy potential adverse effect relate cytokine release syndrome neurologic toxicity compliance risk evaluation mitigation strategy rem program require fda yescarta medicine manage adverse effect therapy tocilizumab corticosteroid available sufficient quantity adequately control effect andor detrimental impact efficacy treatment source clinical commercial supply material manufacture process yescarta develop robust reliable process limit contamination risk engineering patient cell vivo infuse engineer cell patient conditioning patient chemotherapy advance administer therapy increase risk adverse effect use engineer cell potential cancer treatment recent development broadly accept physician patient hospital cancer treatment center payer medical community able establish demonstrate medical community safety efficacy yescarta potential advantage effect compare exist future therapeutic fail overcome significant challenge sale yescarta result operation stock price adversely affect require pay significant damage merck inc merck result jurys finding willfully infringe patent own merck idenix subsidiary december idenix universita degli studi cagliari udsg centre national recherche scientifique luniversit montpellier sue district court district delaware allege commercialization sofosbuvir infringe idenixs patent patent interference exist patent patent december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos patent patent june court transfer massachusetts litigation district court district delaware idenix acquire merck august prior trial december idenix commit covenant sue respect claim arise patent relate sofosbuvir withdraw patent trial addition idenix decline litigate patent infringement action trial light appeal pende court appeal federal circuit cafc invent subject matter claim patent january district court stay idenixs infringement claim patent pende outcome appeal interference decision patent second idenix interference describe idenix successful persuade united states supreme court consider appeal challenge federal circuit june decision favor second idenix interference ask dismissal judgment enter idenix infringement interference claim jury trial hold december patent december jury find willfully infringe assert claim patent award idenix billion past damage party file posttrial motion briefing district judge hear oral argument september september judge deny idenixs motion enhance damage attorney fee february judge grant motion argue patent invalid lack enablement grant motion invalidate idenixs patent vacates jurys award billion past damage idenix indicate plan appeal decision cafc believe court decision correctly find matter law patent invalid remain confident merit case appeal court decision invalidate idenixs patent overturn appeal require pay material time magnitude payment material adverse impact result operation stock price result operation adversely affect current potential future healthcare reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction unite states pharmaceutical manufacturer brand drug product require pay portion industry fee know brand prescription drug bpd fee calculate base select government sale year percentage total industry government sale annual bpd fee impose pharmaceutical industry billion billion bpd fee expense million million million bpd fee tax deductible november election president trump congress numerous effort repeal amend affordable care act house representative vote pass american health care act ahca repeal provision affordable care act senate consider fail pass ahca comparable measure congress consider legislation repeal replace element affordable care act addition tax cut job act president trump sign law december repeal affordable care act individual health insurance mandate consider key component affordable care act future stability affordable care act result impact business uncertain material addition state propose legislation seeks indirectly directly regulate pharmaceutical drug pricing require biopharmaceutical manufacturer publicly report proprietary pricing information place maximum price ceiling pharmaceutical product purchase state agency propose legislation pass experience additional pricing pressure product example october californias governor sign prescription drug price transparency state bill law require prescription drug manufacturer provide advance notice explanation price increase certain drug exceed specify threshold similar bill previously introduce federal level expect additional legislation introduce year potential effect health insurance market destabilization ongoing repeal replace discussion impact potential change way medicaid program finance likely affect patient source insurance resultant drug coverage discussion continue federal level policy allow require government directly negotiate drug price pharmaceutical manufacturer medicare patient require manufacturer pay high rebate medicare state flexibility drug cover medicaid program policy proposal impact reimbursement product discussion center legislation permit reimportation prescription medication canada country difficult predict impact legislation executive action medicaid flexibility use reimbursement product united states include potential importation generic version product yescarta administer inpatient basis possible federal government reimbursement program like medicare medicaid insufficient cover complete cost associate therapy impact willingness hospital offer therapy doctor recommend therapy lessen attractiveness therapy patient adverse effect sale yescarta result operation addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment market sell product government health authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service significant portion sale majority product subject significant discount list price face significant competition face significant competition global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance ease use price insurance reimbursement coverage distribution marketing hiv product compete primarily product viiv healthcare company viiv market fixeddose combination product compete biktarvy descovy odefsey genvoya stribild compleraeviplera atripla truvada example product market viiv include tivicay dolutegravir triumeq abacavirdolutegravirlamivudine juluca dolutegravirrilpivirine compete hiv product addition lamivudine market viiv compete emtricitabine active pharmaceutical ingredient emtriva component biktarvy descovy odefsey genvoya stribild compleraeviplera atripla truvada tybost compete ritonavir market abbvie inc abbvie face competition generic hiv product generic version lamivudine combivir lamivudine zidovudine available united states certain country generic version efavirenz component atripla available united states canada europe observe pricing pressure relate efavirenz component atripla sale tdf active pharmaceutical ingredient stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread face generic competition european union united states certain country addition emtricitabine active pharmaceutical ingredient truvada face generic competition european union truvada face generic competition european union certain country outside united states hcv product sovaldi harvoni epclusa vosevi compete primarily mavyret glecaprevirpibrentasvir market abbvie zepatier elbasvir grazoprevir market merck hbv product vemlidy viread hepsera face competition exist therapy treat patient hbv hbv product face competition generic version tdf hbv product compete baraclude entecavir oral nucleoside analog market bristolmyer squibb company bm generic entecavir tyzekasebivo telbivudine oral nucleoside analog market novartis pharmaceutical corporation novartis yescarta expect compete company develop advanced cell therapy treatment relapsedrefractory diffuse large bcell lymphoma include novartis letairis compete tracleer bosentan opsumit macitentan market actelion pharmaceutical inc adcirca tadalafil market united therapeutics corporation pfizer inc letairis expect face generic competition united states start july ranexa compete predominantly generic compound distinct class drug treatment chronic angina united states include generic andor brand betablocker calcium channel blocker longacte nitrate ranexa expect face generic competition united states start addition number company pursue development technology competitive exist product research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program competitor gain market share result new technology commercialization strategy adversely affect result operation stock price law regulation applicable health care industry impose new obligation require change business practice restrict operation future health care industry subject federal state international law regulation pertain drug reimbursement rebate price report health care fraud abuse datum privacy security united states law include antikickback false claim law law regulation relate medicare medicaid programs federal state program medicaid rebate statute individual state law relate pricing sale marketing practice health insurance portability accountability act hipaa federal state law relate privacy security health information violation law relate regulation punishable criminal andor civil sanction include instance substantial fine civil monetary penalty exclusion participation federal state health care program include medicare medicaid veterans administration health program federal employee health benefit program action executive oversee business burdensome remediation measure addition law regulation broad scope subject change evolving interpretation require incur substantial cost associate compliance alter sale marketing practice violation law allegation violation result negative publicity consequence harm reputation disrupt business adversely affect result operation event occur business stock price materially adversely affect recently enhance scrutiny companysponsore patient assistance program include insurance premium copay assistance program donation thirdparty charity provide assistance enhance scrutiny government reimbursement support offering clinical education program promotional speaker program agents vendor donation recipient deem fail comply law regulation government guidance area subject criminal civil sanction similar violation competitor negatively impact industry reputation increase scrutiny business product description government investigation relate litigation note commitment contingency legal proceeding note consolidated financial statement include item annual report approximately product sale occur outside united states currency fluctuation hedging expense cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency primarily euro face exposure adverse movement foreign currency exchange rate dollar strengthen foreign currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative value sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar use foreign currency exchange forward option contract hedge percentage forecast international sale primarily denominate euro hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay foreign currency exchange net hedge unfavorable impact product sale million year end december compare period predict future fluctuation foreign currency exchange rate dollar dollar appreciate significantly certain currency hedge program sufficiently offset effect appreciation result operation adversely affect stock price decline additionally expense recognize relation hedging activity cause earning fluctuate level hedging expense recognize particular period impact change interest rate spread foreign currency hedge dollar significant safety issue arise market product product candidate future sale reduce adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case postapproval use product long period time patient underlie health problem take numerous medicine expect continue find new issue safety resistance drug interaction issue require provide additional warning contraindication label narrow approve indication reduce market acceptance product regulatory authority move active transparent pharmacovigilance make great amount standalone safety information clinical trial datum directly available public website mean periodic safety update report summarie risk management plan summarie adverse event datum safety information appropriate context expertise misinterpret lead misperception legal action potentially cause product sale stock price decline yescarta novel car cell therapy treatmentrelate adverse effect appropriately recognize manage treat medical staff toxicity result personalize cell therapy typically encounter general patient population medical personnel common medicine academic medical center hospital help manage adverse effect yescarta tocilizumab corticosteroid available sufficient quantity adequately control adverse effect andor detrimental impact efficacy treatment train expect continue train medical personnel understand effect profile yescarta compliance rem program require fda yescarta assurance efficacy training effort inadequate training recognize manage potential adverse effect yescarta disregard modification training medical staff result severe prolong toxicity patient death safety resistance drug interaction issue arise market product sale product limit halt regulatory authority result operation adversely affect operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis maintain compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda european medicines agency ema comparable regulatory agency country continue clinical trial product currently approve additional use anticipate file marketing approval additional country additional indication product year product fail receive marketing approval timely basis manufacture sell product subject extensive regulation review discovery previously unknown problem market product problem manufacture safety report promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement include related promotion manufacturing subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution example fda rule require conduct postapproval clinical study assess know risk signal risk identify unexpected risk implement rem product include medication guide patient package insert communication plan healthcare provider element fda deem necessary assure safe use drug include impose certain restriction distribution use product failure comply requirement impose fda result significant civil monetary penalty operating result adversely affect result anticipate timeline clinical trial uncertain support continue development product candidate adversely affect prospect future revenue growth require demonstrate safety efficacy product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product example terminate phase study treatment rheumatoid arthritis cystic fibrosis phase study treatment hepatitis virus determine study datum show insufficient evidence treatment benefit product candidate fails achieve primary endpoint clinical trial safety issue arise result clinical trial inadequate support regulatory approval product candidate commercialization product candidate delay halt addition face challenge clinical trial protocol design clinical trial product candidate pipeline delay terminate prospect future revenue growth adversely impact example face numerous risk uncertaintie product candidate include descovy preexposure prophylaxis prep selonsertib treatment nonalcoholic steatohepatitis nash andecaliximab treatment gastric cancer axicabtagene ciloleucel treatment second line diffuse large bcell lymphoma filgotinib treatment rheumatoid arthritis crohns disease ulcerative colitis currently phase clinical trial prevent completion development product candidate risk include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain fda regulatory body approval result product candidate successfully commercialize strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program pipeline complete timely basis prospect future revenue growth adversely impact addition clinical trial involve commercial product raise new safety issue exist product turn decrease revenue harm business reliance thirdparty contract research organization conduct clinical trial unable directly control timing conduct expense quality clinical trial extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent party contract research organization cro perform clinical study include document preparation site identification screen preparation prestudy visit training program management bioanalytical analysis important aspect service perform cros direct control dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform thirdparty cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely affect depend relationship company sale marketing performance technology development logistic commercialization product candidate revenue failure maintain relationship poor performance company dispute company negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance certain territory include collaboration janssen sciences ireland odefsey compleraeviplera symtuza europe bms atripla europe country rely international distributor sale certain product relationship involve clinical development product partner reliance collaborative relationship pose number risk include risk unable control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline yescarta available rem program require fda mitigate potential risk product hospital associate clinic certify rem program permit dispense yescarta relevant staff involve prescribing dispensing administer yescarta train rem program requirement successfully complete rem program knowledge assessment failure hospital clinic enroll yescarta rem program successfully complete comply program requirement result regulatory action fda decrease sale yescarta harm business reputation yescarta rely technology partner assist development maintenance kite konnect platform platform critical ensure positive prescriber patient experience chain identity chain custody yescarta technology platform incomplete insufficiently maintain develop technological issue experience disruption sale logistic yescarta business extend significant period time need expend considerable resource time repair improve platform cooperation partner addition rely site collect patient white blood cell know apheresis center shipper courier hospital logistical collection patient white blood cell ultimate delivery yescarta patient disruption difficulty incur vendor result product loss regulatory action harm yescarta business reputation addition ensure apheresis center prepare ship cell manufacture facility plan conduct quality certification apheresis center apheresis center choose participate certification process unable complete certification timely manner delay restrain manufacturing commercialization effort result sale yescarta limit harm result operation success depend significant degree ability defend patent intellectual property right domestically internationally able obtain effective patent protect technology use competitor patent company require stop pay use require technology patent proprietary right important business success depend significant degree ability obtain patent license patent right preserve trade secret internal knowhow defend infringement effort invalidate patent operate infringe intellectual property properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate litigation interference proceeding determine right patent validity patent grant litigation interference proceeding unpredictable expensive divert management attention operation ultimately successful result operation adversely affect event example tdf active pharmaceutical ingredient stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread face generic competition european union united states certain country addition emtricitabine active pharmaceutical ingredient truvada face generic competition european union truvada face generic competition european union certain country outside united states letairis expect face generic competition united states start july entry generic product lead market share price erosion negative impact business result operation addition patent cover ranolazine active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level obtain patent formulation characteristic plasma level achieve yescarta composition matter patent expire european union european union united states patent application pende related kite proprietary manufacturing process obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country generic manufacturer seek continue seek fda approval market generic version product abbreviate new drug application anda application form typically manufacturer seek approval generic drug description anda litigation note commitment contingency legal proceeding note consolidated financial statement include item annual report form risk factor entitle litigation generic manufacturer increase expense continue reduce earning unsuccessful lawsuit claim patent narrow invalidated generic version product launch prior patent expiry begin success depend large ability operate infringe patent proprietary right party infringe valid patent party require pay significant monetary damage prevent commercialize product require obtain license party able obtain alternative technology require license commercially reasonable term fail obtain license alternative technology unable develop commercialize product example aware patent patent application own party party claim cover use sofosbuvir axicabtagene ciloleucel bictegravir description litigation sofosbuvir axicabtagene ciloleucel bictegravir note commitment contingency legal proceeding note consolidated financial statement include item annual report risk factor entitle hcv product prove infringe patent party require pay significant monetary damage adversely affect financial result begin party successful establish exclusive right axicabtagene ciloleucel anticipate revenue earning sale product adversely affect beginning aware patent nos assign department health human service purport claim process protect primate host infection immunodeficiency retrovirus administer combination emtricitabine tenofovir tdf prior exposure host immunodeficiency retrovirus contact department health human service scope relevance patent explain believe patent valid patent office give relevant prior art physician patient claim method year center disease control prevention file application patent furthermore rely unpatented trade secret improvement unpatente internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret internal knowhow technological innovation know independently discover competitor agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret internal knowhow technological innovation confidential information know independently discover competitor enter dispute ownership invention business result operation adversely affect hcv product prove infringe patent party require pay significant monetary damage adversely affect financial result patent patent application claim sofosbuvir sovaldi chemical entity metabolite fixeddose combination ledipasvir sofosbuvir harvoni sofosbuvir velpatasvir epclusa sofosbuvir velpatasvir voxilaprevir vosevi aware patent patent application own party future allege party cover use hcv product party obtain valid enforceable patent successfully prove infringement patent hcv product require pay significant monetary damage current legal proceeding significance relate sofosbuvir include litigation idenix pharmaceuticals inc idenix march european patent office epo grant idenix european patent patent correspond patent day patent grant file opposition epo seek revoke patent opposition hearing hold february epo rule favor revoke patent idenix appeal description idenix litigation note commitment contingency legal proceeding note consolidated financial statement include item annual report litigation merck august merck contact request pay royalty sale sofosbuvir obtain license patent patent patent patent coown ionis pharmaceuticals inc patent cover compound include relate sofosbuvir file lawsuit august district court northern district california seek declaratory judgment merck patent invalid infringe patent prosecution merck amend patent application attempt cover compound relate sofosbuvir initially march jury determine establish merck patent invalid lack write description lack enablement award merck million damage june court rule favor defense unclean hand determine merck recover damage patent judge determined merck require pay attorney fee exceptional nature case july court issue decision setting attorney fee award gilead merck file notice appeal cafc court decision defense unclean hand award attorney fee appeal issue relate invalidity merck patent cafc hear oral argument february decision defense unclean hand reverse appeal merck patent uphold require pay damage royalty sale sofosbuvircontaine product follow appeal event judge indicate determine royalty necessary conclusion appeal case litigation university minnesota university minnesota university obtain patent patent purport broadly cover nucleosides antiviral anticancer activity august university file lawsuit district court district minnesota allege commercialization sofosbuvircontaine product infringe patent believe patent invalid infringe continue commercialization sofosbuvir october court grant motion transfer case california file petition inter part review uspto allege assert claim invalid anticipation obviousness petition inter part review file initiative medicine access knowledge october receive notice initiative medicine access knowledge imak submit multiple petition request inter parte review uspto patent trial appeal board ptab allege certain patent associate sofosbuvir invalid novel obvious strongly believe imak petition merit sofosbuvir approve hcv drug kind novel obvious accordingly defend allegation ptab decide initiate inter parte review decision expect year later party appeal ptab decision cafc european patent claim february party file opposition epo request revocation grant european patent cover sofosbuvir expire october epo uphold validity certain claim sofosbuvir patent anticipate challenger appeal decision favor patent appeal decision seek restore original claim original oppose party appeal request revocation appeal process year april party file opposition epo request revocation grant european patent relate sofosbuvir expire predict ultimate outcome intellectual property claim relate hcv product spend continue spend significant resource defend claim unsuccessful lawsuit require pay significant monetary damage significant negative effect financial result party successful establish exclusive right axicabtagene ciloleucel anticipate revenue earning sale product adversely affect october acquire kite whollyowne subsidiary acquisition acquire axicabtagene ciloleucel car cell therapy october receive approval fda axicabtagene ciloleucel know commercially yescarta patent patent application claim axicabtagene ciloleucel chimeric dna segment party obtain right patent allegedly prevent attempt prevent commercialize axicabtagene ciloleucel require obtain license order commercialize axicabtagene ciloleucel example aware juno therapeutics inc juno exclusively license patent patent issue sloan kettering cancer center september juno sloan kettering cancer center file lawsuit kite district court central district california allege commercialization axicabtagene ciloleucel infringe patent october follow fda approval yescarta juno file second complaint allege axicabtagene ciloleucel infringe patent juno subsequently move dismiss september complaint maintain october complaint august kite file petition inter parte review uspto allege assert claim patent invalid obvious december ptab determine claim patent invalid obviousness february kite file notice appeal cafc appeal currently pende predict ultimate outcome intellectual property claim relate axicabtagene ciloleucel junos patent uphold valid juno successfully prove infringement patent axicabtagene ciloleucel prevent sell yescarta able obtain license patent license available commercially reasonable term adversely impact business result operation manufacturing problem include thirdparty manufacturer corporate partner cause inventory shortage delay product shipment regulatory approval adversely affect result operation order generate revenue product able produce sufficient quantity product satisfy demand product result complex manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation product manufacture facility thirdparty manufacturer corporate partner depend party perform manufacturing activity effectively timely basis majority solid dose product thirdparty manufacturer corporate partner subject good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard define fda ema similar regulation effect jurisdiction thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval writeoff cost manufacturing batch fail pass quality inspection meet regulatory approval addition thirdparty manufacturer corporate partner able produce product limit number facility limited manufacturing capacity certain product able locate additional replacement facility reasonable basis sale product adversely impact reliance limit number facility extent risk materialize affect performance obligation financial result adversely affect manufacturing operation subject routine inspection regulatory agency unable remedy deficiency cite fda inspection currently market product time regulatory approval product development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country approval product candidate delay production market product interrupt anticipate revenue stock price adversely affect limited experience manage cell engineering process process difficult expensive approach take current future competitor sure manufacturing process employ result engineer cell safe effective addition encounter difficulty production particularly scale validate initial production meet patient demand ensure absence contamination problem include difficulty production cost yield quality control include stability product quality assurance testing operator error shortage qualified personnel compliance strictly enforce federal state foreign regulation contaminant discover supply yescarta manufacturing facility manufacturing facility need close extend period time investigate remedy contamination require substantial resource management attention assure stability issue relate manufacture yescarta occur future issue remedied timely basis addition fail manage logistic collect ship patient material manufacturing site ship yescarta patient logistical shipment delay problem cause vendor factor control weather natural disaster prevent delay delivery product product candidate patient additionally require maintain complex chain identity custody respect patient material material move manufacturing facility manufacturing process patient failure maintain chain identity custody result patient death loss product regulatory action adverse effect reputation stock price able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial manufacture product unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue supplier key component material name new drug application maa file fda ema regulatory authority product candidate seek marketing approval significant delay occur qualification new supplier require manufacturer qualified regulatory authority manufacturer continue expend time money effort area production quality control ensure compliance gmp manufacturer subject regular periodic inspection regulatory authority follow initial approval result inspection regulatory authority determine equipment facility laboratory process comply applicable regulation condition product approval regulatory authority suspend manufacturing operation manufacture operation single supplier product suspend unable generate sufficient quantity commercial clinical supply product meet market demand turn decrease revenue harm business addition delivery material supplier interrupt reason unable ship certain product commercial supply supply product development clinical trial addition product material utilize operation facility able replace timely manner commercially reasonable term problem single supplier depend include event disaster include earthquake equipment failure difficulty negatively impact development commercialization effort significant portion raw material intermediate manufacture antiviral product supply thirdparty manufacturer corporate partner outside united states result political economic factor specific country region include change interpretation trade regulation compliance requirement tax legislation limit prevent party outside united states supply material adversely affect ability manufacture supply antiviral product meet market need material adverse effect operating result encounter difficulty ability provide product product candidate patient jeopardized litigation generic manufacturer increase expense continue reduce earning unsuccessful lawsuit claim patent narrow invalidated generic version product launch prior patent expiry approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug anda application form typically manufacturer seek approval generic drug seek approval generic version product nce status generic manufacturer submit anda fda year brand product approval sofosbuvir date fall december consequently possible generic manufacturer file anda sofosbuvir december current legal proceeding significance generic manufacturer include mylan february receive notice mylan pharmaceuticals inc mylan submit anda fda request permission manufacture market generic version tybost cobicistat notice mylan allege patent cover cobicistat invalid obvious mylan generic product infringe invalid claim march file lawsuit mylan district court district delaware district court northern district west virginia party agree dismiss action west virginia trial delaware stay patent suit cover tybost list orange book stribild genvoya november receive notice mylan submit anda fda request permission manufacture market generic version evotaz atazanavircobicistat challenge validity cobicistat compound patent cite argument ongoing litigation involve tybost december file lawsuit mylan district court northern district west virginia amneal receive notice amneal pharmaceutical llc amneal submit anda fda request permission manufacture market generic version truvada low dosage strength notice amneal allege patent associate emtricitabine invalid unenforceable andor infringe amneal manufacture use sale generic version truvada low dosage strength july file lawsuit amneal district court district delaware infringement patent natco teva february receive notice natco pharma limited natco teva pharmaceuticals teva submit anda fda request permission manufacture market generic version sovaldi tevas notice allege patent associate sofosbuvir invalid unenforceable andor infringe tevas manufacture use sale generic version sovaldi natcos notice allege patent associate sofosbuvir invalid unenforceable andor infringe natcos manufacture use sale generic version sovaldi natco challenge patent list orange book sovaldi evaluate notice letter determine step predict ultimate outcome forego action litigation generic manufacturer spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection product substantially shorten patent cover product invalidate fda approve request manufacture generic version products united states prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation import country product available low price unapprove generic counterfeit version product negative impact reputation business price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market hiv hbv hcv product agree available substantially reduce price certain low middleincome country participate gilead access program export low middleincome country united states europe high price market revenue adversely affect addition enter voluntary licensing agreement generic drug company india south africa china licensing agreement medicine patent pool unite nationsbacke public health organization allow generic drug company manufacture generic version hiv hbv product incorporate licensed compound taf cobicistat elvitegravir bictegravir distribution certain low middleincome country enter licensing agreement generic manufacturers india egypt pakistan produce distribute generic version hcv product certain low middleincome country generic version hiv hbv hcv product license reexporte united states europe market outside low middleincome country revenue adversely affect addition purchase product country sell price relatively low resale country sell price relatively high adversely impact revenue gross margin cause sale fluctuate quarter quarter example european union require permit product purchase country sell country purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter reflect actual consumer demand give quarter quarterly fluctuation impact earning adversely affect stock price harm business aware existence buyer club world promote personal importation generic version hcv product approve use country import result patient risk take unapproved medication purport potency claim contain harmful substance extent patient unapproved generic version medication injure cure product brand commercial scientific reputation hcv product harm party illegally distribute sell counterfeit version product meet rigorous quality standard manufacturing supply chain example quarter bottle counterfeit drug label harvoni brand discover retail pharmacy chain pharmaceutical wholesaler japan investigate matter accelerate plan change product packaging counterfeit difficult cooperate continue cooperate japanese health ministry quarter bottle counterfeit drug label sovaldi brand discover retail pharmacy chain pharmaceutical wholesaler germany investigate matter determine number wholesaler obtain sovaldi unapproved source cooperate continue cooperate german regulatory authority report product label epclusa available multiple country determine authentic product base sample analysis lot number work regulatory authority investigate matter actively action discourage counterfeit product world include work local regulatory legal authority enforce law counterfeit drug counterfeit drug pose risk patient health safety reputation business suffer result counterfeit drug sell brand expensive litigation government investigation increase expense continue reduce earning involve number litigation investigation disputerelate matter require expend substantial internal financial resource expect matter continue require high level internal financial resource foreseeable future matter reduce continue reduce earning require significant management attention description litigation investigation disputerelate matter note commitment contingency legal proceeding note consolidated financial statement include item annual report outcome legal proceeding legal proceeding bring investigation investigation initiate disputerelate matter inherently uncertain adverse development outcome result significant expense monetary damage penalty injunctive relief significantly reduce earning cash flow harm business country require grant compulsory license product patent enforce number develop country government official interested group suggest pharmaceutical company drug hiv hcv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example grow attention availability hcv therapy activist advocate increase availability hcv therapy mean include compulsory license government malaysia exercise government right section malaysian patent act practice patent invention sofosbuvir period year use government hospital clinic challenge malaysian government action past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread compulsory license permit generic manufacturing override product patent hiv hcv product require grant compulsory license product reduce earning cash flow harm business addition certain country permit enforcement patent permit patent issue thirdparty manufacturer able sell generic version product country example brazilian health regulatory agency reject patent application relate sofosbuvir hcv product successfully appeal decision application examination brazilian patent trademark office sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale face significant liability result product cover insurance liability materially reduce earning testing manufacturing marketing use commercial product product candidate development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company sufficient insurance coverage product liability arise addition cost defend lawsuit pay damage product liability claim exceed insurance coverage maintain adequate coverage claim exceed coverage financial condition adversely affect addition negative publicity associate claim regardless merit decrease future demand product impair financial condition business disruption natural manmade disaster harm future revenue worldwide operation subject business interruption stem natural manmade disaster uninsured inadequately insure corporate headquarters foster city santa monica location house majority activity san dimas verne oceanside segundo manufacturing facility locate california seismically active region carry adequate earthquake insurance significant recovery time require resume operation financial condition operating result materially adversely affect event major earthquake addition yescarta business reliant ability manage logistic collect ship patient material manufacturing facility ship yescarta patient logistical shipment delay cause natural manmade disaster prevent delay delivery product patient harm yescarta business dependent information technology system infrastructure datum dependent information technology system infrastructure datum include new kite konnect platform multitude complexity computer system inherently vulnerable service interruption destruction malicious intrusion random attack likewise datum privacy security breach employee pose risk sensitive datum include intellectual property trade secret personal information employee patient customer business partner expose unauthorized person public cyberattack increase frequency sophistication intensity cyberattack include deployment harmful malware denialofservice social engineering mean affect service reliability threaten datum confidentiality integrity availability business technology partner face similar risk security breach system adversely affect security posture invest continue invest protection datum information technology infrastructure assurance effort effort partner vendor prevent service interruption identify breach system adversely affect business operation andor result loss critical sensitive information result financial legal business reputational harm addition liability insurance sufficient type cover claim relate security breach cyberattack relate breach regulator globally impose great monetary fine privacy violation example european union adopt new law govern data practice privacy call general datum protection regulation gdpr effective law establish new requirement handle personal datum noncompliance gdpr result monetary penalty worldwide revenue gdpr change law regulation associate enhance protection certain type sensitive datum healthcare datum personal information greatly increase cost provide product service prevent offer certain service jurisdiction operate change effective income tax rate reduce earning subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law predict form time potential legislative change material adverse impact result operation example united states recently enact significant tax reform certain provision new law significantly affect accounting change currently consider provisional change materially measurement period issuance anticipate guidance finalization certain accounting method election note income taxis note consolidated financial statement include item annual report additional detail addition significant judgment require determine worldwide provision income taxis factor favorable unfavorable effect income tax rate include limited change forecast demand hcv product portion nontax deductible annual bpd fee accounting stock option sharebase award merger acquisition ability manufacture product cork ireland facility amortization certain acquisition relate intangible receive tax benefit future level spending change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact consolidate result operation income tax return subject audit federal state foreign tax authority currently examination internal revenue service tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction resolution exposure report period material impact result operation period fail attract retain highly qualified personnel unable successfully develop new product candidate conduct clinical trial commercialize product candidate future success depend large continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization face competition personnel company university public private research institution government entity organization competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit able attract retain quality personnel acceptable term additionally change immigration work authorization law regulation difficult employee work transfer jurisdiction operation impair ability attract retain qualified personnel unsuccessful recruitment retention effort business harm assurance pay dividend continue repurchase stock board director authorize dividend program intend pay quarterly dividend share subject quarterly declaration board director board director approve repurchase billion common stock billion available repurchase december future declaration time dividend andor time stock repurchase subject capital availability determination board director cash dividend andor stock repurchase good interest stockholder compliance respective law agreement applicable declaration payment cash dividend repurchase stock ability pay dividend andor repurchase stock depend factor cash balance potential future capital requirement strategic transaction include acquisition debt service requirement result operation financial condition factor control board director deem relevant reduction elimination dividend payment dividend program andor stock repurchase negative effect stock price item unresolved staff comment applicable item property corporate headquarters locate foster city california house administrative manufacturing activity facility oceanside santa monica california seattle washington alberta canada manufacturing facility segundo verne oceanside san dimas california alberta canada cork ireland global operation include office europe north america asia south america africa australia middle east believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet expect longterm growth need item legal proceeding description significant pende legal proceeding note commitment contingency legal proceeding note consolidated financial statement include item annual report incorporate reference item safety disclosure applicable item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild follow table set forth high low intraday sale price share common stock nasdaq global select market period indicate price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low high low quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record include share hold broker bank nominee dividend declare pay quarterly cash dividend aggregate billion common share declare pay quarterly cash dividend aggregate billion common share note stockholder equity note consolidated financial statement include item annual report additional information performance graph follow graph compare cumulative total stockholder return past year index standard poor stock index label index nasdaq biotechnology index label nbi index stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year note section solicit material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nbi index index december dividend reinveste issuer purchase equity security quarter board director authorize billion share repurchase program program repurchase open market privately negotiate transaction start repurchase program april repurchase retire million share common stock million open market transaction program table summarize stock repurchase activity month end december maximum fair total number value share total number average share purchase share price pay publicly purchase purchase share announce program program thousand dollar thousand million october october november november december december total note difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation item select financial datum gilead sciences inc select consolidated financial datum million share datum year end december consolidated statement income datum total revenue total cost expense income operation provision income taxis net income net income attributable gilead net income share attributable gilead common stockholder basic share share calculation basic net income share attributable gilead common stockholder dilute share share calculation dilute cash dividend declare share december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation longterm debt include current portion retain earning total stockholder equity note management discussion analysis financial condition result operation include item annual report description result operation december record estimate billion net charge relate enactment tax cut job act note income taxis note consolidated financial statement include item annual report additional detail connection acquisition kite pharma inc issue billion aggregate principal senior unsecured note register offering draw billion aggregate principal term loan facility credit agreement billion repay december issue billion principal senior unsecured note register offering repay million principal balance convertible senior note million principal balance senior unsecured note december issue billion principal senior unsecured note register offering repay million principal balance convertible senior note issue billion principal senior unsecured note register offering repay million principal balance convertible senior note million principal balance senior unsecured note december million fiveyear revolve credit facility agreement repay billion principal balance convertible senior note repay million fiveyear revolve credit facility agreement retrospectively adopt accounting standard update balance sheet classification defer taxis require defer tax asset liability classify noncurrent balance sheet result reclassify defer tax asset total current asset longterm asset defer tax liability accrue liability longterm obligation year present retrospectively adopt accounting standard update simplifying presentation debt issuance cost require presentation debt issuance cost direct deduction carrying recognize debt liability balance sheet result reclassify unamortized debt issuance cost asset long term debt include current portion year present item management discussion analysis financial condition result operation follow management discussion analysis financial condition result operation mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note consolidated financial statement disclosure include annual report include disclosure item risk factor consolidate financial statement prepare accordance generally accept accounting principle present dollar management overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world operation country worldwide headquarters foster city california gileads primary area focus include hivaid liver disease hematologyoncology inflammationrespiratory disease seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy portfolio market product include ambisome atripla biktarvy cayston compleraeviplera descovy emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada tybost vemlidy viread vosevi yescartatm zydelig international commercial sale operation marketing subsidiary country sell distribute certain product corporate partner royaltypaye collaborative agreement business highlight mark operational excellence business accomplish key goal position future growth observe strong performance hiv cardiovascular product continue execute maximize opportunity hcv change competitive landscape addition continue advance product pipeline therapeutic area goal deliver bestinclass drug advance current standard care andor address unmet medical need recent key development include key announcement fda grant priority review new drug application nda biktarvy fixeddose combination bictegravir bic novel investigational integrase strand transfer inhibitor emtricitabinetenofovir alafenamide taf treatment hiv infection addition marketing authorization application biktarvy fully validate evaluation european medicine agency ema receive food drug administration fda approval biktarvy february european commission grant marketing authorization vemlidy oncedaily tablet treatment chronic hepatitis virus hbv infection adult adolescent aged year old body weight european commission fda approve vosevi oncedaily single tablet regimen treatment hcv infection adult genotype vosevi single tablet regimen patient previously fail therapy directacting antiviral daa treatment late regimen portfolio sofosbuvirbase hcv daa treatment announce new licensing agreement medicine patent pool mpp united nationsbacke public health organization expand access bic agreement mpp sublicense right bic generic drug company india china south africa manufacture therapy contain bic distribution certain low middleincome country china food drug administration approve sovaldi treatment hcv infection sovaldi approve treatment adult adolescent aged year infect hcv genotype component combination antiviral treatment regiman sovaldi hcv medicine approve china fda approve expand labeling epclusa alloral pangenotypic oncedaily single tablet regimen treatment adult hcv infection include use patient coinfecte hiv european commission extend marketing authorization harvoni include treatment hcv infection adolescent infect genotype harvoni daa regiman receive marketing authorization european union extend use adolescent population fda approve supplemental indication harvoni sovaldi treatment hcv infection adolescent cirrhosis compensate cirrhosis year age old weighing kilogram harvoni approve pediatric patient genotype hcv infection sovaldi approve pediatric patient genotype hcv infection combination ribavirin acquisition october complete tender offer outstanding common stock kite pharma inc kite share cash approximately billion exclude approximately billion relate portion replace stockbased award attributable post combination period finance transaction billion aggregate principal senior unsecured note issue september billion aggregate principal term loan facility credit agreement enter september draw october billion repay december cash hand kite cell therapy express chimeric antigen receptor car engineer cell receptor depend type cancer acquisition result kite whollyowne subsidiary establish leader cellular therapy kite acquisition acquire axicabtagene ciloleucel car cell therapy october receive approval fda axicabtagene ciloleucel know commercially yescarta make car cell therapy treatment adult patient relapse refractory large cell lymphoma line systemic therapy include diffuse large bcell lymphoma transform follicular lymphoma primary mediastinal bcell lymphoma file marketing authorization application axicabtagene ciloleucel treatment indication ema represent know submission europe car cell therapy approval europe expect half assurance receive approval timely basis addition axicabtagene ciloleucel acquire therapy candidate clinical trial hematologic cancer solid tumor include kite car cell therapy candidate target bcell maturation antigen express multiple myeloma december acquire issue outstanding stock cell design labs inc cell design labs privately hold company addition approximately share cell design lab obtain acquisition kite acquisition gain new technology platform enhance research development effort cellular therapy note acquisition note consolidated financial statement include item annual report additional information acquisition kite cell design labs financial highlight total revenue decrease billion total product sale decrease billion compare billion billion respectively primarily competitive dynamic hcv market lower sale hcv product partially offset high sale hiv product united states product sale billion compare billion europe product sale billion compare billion sale international location billion compare billion research development expense decrease billion compare primarily impact business development activity result upfront collaboration expense relate license collaboration agreement galapagos galapagos acquire process iprd expense relate purchase nimbus apollo inc nimbus iprd impairment charge ongoing milestone payment partially offset acquire iprd expense relate purchase cell design lab sell general administrative sga expense increase billion compare primarily cost associate acquisition kite higher brand drug prescription bpd fee expense provision income taxis increase billion compare billion primarily estimated billion net charge relate enactment tax cut job act tax reform fourth quarter net income attributable gilead billion diluted share compare billion diluted share primarily low product sale impact tax reform december billion cash cash equivalent marketable security compare billion december generate billion operate cash flow pay cash dividend billion repurchase total million share million open market transaction outlook continue maintain strong focus operational excellence financial discipline perspective continue invest new ongoing clinical study support exist product product candidate expect forward number clinical study new product candidate include advance cell therapy pipeline continue progression phase study selonsertib nonalcoholic steatohepatitis nash filgotinib rheumatoid arthritis inflammatory bowel disease order develop product pipeline focus leverage balance sheet pursue partner acquisition opportunity fit longterm strategic plan commercial perspective support launch biktarvy continue promote use exist tafcontaining regimen addition believe truvada preexposure prophylaxis prep continue integral growth hiv united states community embrace public health benefit prevention hcv expect decline product sale major market result increase competition hcv revenue drive variable patient start net pricing market share treatment duration treatment duration stabilize variable pricing regimen gravitate week regimen price anticipate pricing market share stabilize mid predictable slightly decline patient start move forward cell therapy continue promote use yescarta united states prepare anticipate approval europe continue help ensure patient access product world include gilead access program million people receive hiv medicine low middleincome country progress initiative subject number uncertainty include limited continuation uncertain global macroeconomic environment additional pricing pressure payer competitor slow anticipate growth hiv product increase discount chargeback rebate ongoing contract future negotiation commercial government payer market share price erosion cause introduction generic version truvada outside united states viread letairis united states inaccuracy hcv patient start estimate potential amendment affordable care act government action effect lower price large anticipate shift payer mix highly discount payer segment volatility foreign currency exchange rate result operation total revenue follow table summarize period period change product sale royalty contract revenue million percentage change change revenue product sale royalty contract revenue total revenue product sale compare total product sale billion compare billion primarily decrease antiviral product sale antiviral product sale include sale hiv hbv hcv product billion compare billion hiv hbv product sale billion compare billion increase primarily drive continued uptake tafbase product partially offset decrease sale tenofovir disoproxil tdfbase product hcv product sale consist harvoni epclusa sovaldi vosevi billion compare billion decline hcv product sale major market result increase competition low total market patient start product sale include sale letairis ranexa ambisome billion increase compare billion letairis expect face generic competition united states start july product sale generate outside united states face exposure movement foreign currency exchange rate primarily euro foreign currency exchange contract hedge percentage foreign currency exposure foreign currency exchange net hedge unfavorable impact million product sale compare record product sale net estimate mandatory supplemental discount government payer addition discount private payer include rebate chargeback cash discount prompt payment distributor fee relate cost deduction generally refer grossto net deduction total billion gross product sale compare billion billion billion gross product sale relate government rebate chargeback billion relate cash discount prompt payment distributor fee relate cost product sale united states decrease billion compare billion decline sale hcv product partially offset increase sale hiv hbv product decline sale hcv product primarily lower harvoni sovaldi sale volume result increase competition low total market patient start additionally increase epclusa vosevi sale volume partially offset low average net selling price epclusa pricing regimen gravitate week regimen price increase sale hiv hbv product primarily drive high sale volume tafbase product high average net selling price partially offset decrease tdf base product prior year impact favorable revision rebate reserve million primarily relate tdfbase product product sale europe decrease billion compare billion primarily lower harvoni sovaldi sale volume partially offset high epclusa sale volume foreign currency exchange net hedge unfavorable impact million product sale compare product sale international location decrease billion compare billion primarily low sale japan sale hcv product japan million compare billion period primarily low sale volume result low total market patient start increase competition compare total product sale billion compare billion primarily decrease antiviral product sale antiviral product sale billion compare billion hiv hbv product sale billion compare billion increase primarily drive continued uptake tafbase product partially offset decrease sale tdfbase product hcv product sale billion compare billion decline low sale harvoni sovaldi partially offset sale epclusa launch location product sale include sale letairis ranexa ambisome billion increase compare billion product sale generate outside united states foreign currency exchange net hedge unfavorable impact million product sale compare grosstonet deduction total billion gross product sale compare billion billion billion gross product sale relate government rebate chargeback billion relate cash discount prompt payment distributor fee relate cost increase grosstonet deduction primarily increase discount high percentage sale deeply discount segment hcv product united states product sale united states decrease billion compare billion decline sale hcv product partially offset increase sale hiv hbv product increase sale hiv hbv product primarily drive sale newly launch tafbase product favorable revision rebate reserve million primarily relate tdfbase product product sale europe decrease billion compare billion primarily lower harvoni sovaldi sale volume foreign currency exchange net hedge unfavorable impact million product sale compare product sale international location increase billion compare billion primarily sale japan sale hcv product japan billion compare billion increase primarily drive high sale volume harvoni launch september partially offset mandatory price reduction sovaldi harvoni effective april follow table summarize period period change product sale million percentage change change antiviral product hcv product harvoni epclusa sovaldi vosevi hiv hbv product genvoya truvada atripla descovy odefsey stribild viread compleraeviplera total antiviral product product letairis ranexa ambisome zydelig total product sale percentage meaningful follow additional discussion result product harvoni harvoni sale account total antiviral product sale respectively product sale billion united states million europe million international location product sale billion united states billion europe billion international location product sale billion united states billion europe billion international location decrease compare major market primarily low sale volume united states decrease compare primarily low sale volume low average net selling price partially offset favorable revision sale return reserve million record second quarter number patient start treatment harvoni united states peak half warehoused patient initiate treatment product launch europe decrease compare primarily low sale volume unfavorable foreign currency exchange net hedge international location increase compare primarily high sale japan sales japan billion compare billion drive high sale volume partially offset mandatory price reduction effective april epclusa epclusa approve fda european commission june july respectively epclusa sale account total antiviral product sale respectively product sale billion united states million europe million international location product sale billion united states million europe million international location increase compare major market primarily high sale volume partially offset decrease average net selling price sovaldi sovaldi sale account total antiviral product sale respectively product sale million united states million europe million international location product sale billion united states million europe billion international location product sale billion united states billion europe billion international location decrease compare major market primarily low sale volume drive shift market sovaldi epclusa united states decrease compare primarily low sale volume partially offset favorable revision sale return reserve million record second quarter europe decrease compare primarily low sale volume international location slight decrease primarily low sale japan sale japan million compare million mandatory price reduction effective april low sale volume tafbase regimen genvoya descovy odefsey genvoya approve fda european commission november descovy approve fda european commission april odefsey approve fda european commission march june respectively product sale tafbase regimen billion billion million respectively account total antiviral product sale respectively product sale billion united states million europe million international location product sale billion united states million europe million international location increase compare major market primarily drive high sale volume patient shift away tdfbase regimen europe product sale tafbase regimen continue grow despite availability generic viread truvada country tdfbase regimen stribild compleraeviplera atripla truvada viread product sale tdfbase regimen billion billion billion respectively account total antiviral product sale respectively product sale billion united states billion europe million international location product sale billion united states billion europe million international location product sale billion united states billion europe million international location united states decrease compare primarily low sale volume result continue uptake taf base regimen partially offset increase usage truvada prep europe decrease compare primarily low sale volume result availability generic viread truvada country continue uptake tafbase regimen united states increase compare primarily favorable revision rebate reserve million relate stribild complera quarter europe decrease compare primarily low sale volume result continue uptake tafbase regimen royalty contract revenue follow table summarize period period change royalty contract revenue million percentage change change royalty contract revenue royalty contract revenue slightly compare period decrease compare million decrease compare primarily royalty revenue hoffmanla roche ltd sales tamiflu cost good sell product gross margin follow table summarize period period change product sale cost good sell product gross margin million percentage change change total product sale cost good sell product gross margin decrease product gross margin compare compare primarily change product mix hcv product sale decrease percentage total product sale research development expense follow table summarize period period change expense million percentage change change expense expense summarize consist primarily clinical study perform contract research organization material supply license fee upfront payment collaboration agreement milestone payment personnel cost include salary benefit stockbase compensation overhead allocation consist support facilitiesrelate cost track total expense product candidate therapeutic area development phase manage expense identify activity anticipate perform give period prioritize effort base scientific datum probability successful development market potential available human capital resource consideration continually review pipeline status development necessary reallocate resource portfolio believe good support future growth business follow table provide breakout expense major cost type million percentage clinical study outside service personnel infrastructure expense facility cost iprd impairment charge acquire iprd upfront collaboration expense total expense decrease billion compare primarily impact business development activity result collaboration expense relate license collaboration agreement galapago acquire iprd expense relate purchase nimbus iprd impairment charge ongoing milestone payment partially offset acquire iprd expense relate purchase cell design lab expense increase billion compare primarily overall progression clinical study include ongoing milestone payment purchase fda priority review voucher upfront collaboration expense relate license collaboration agreement galapago acquire iprd expense relate purchase nimbus iprd impairment charge result termination clinical development momelotinib simtuzumab sell general administrative expense follow table summarize period period change sga expense million percentage change change sga expense sga expense relate sale marketing finance human resource legal administrative activity expense consist primarily personnel cost facility overhead cost outside marketing advertising legal expense general administrative cost sga expense include bpd fee united states pharmaceutical manufacturer brand drug product require pay portion bpd fee estimate base select government sale calendar year percentage total industry government sale truedup receipt invoice internal revenue service irs sga expense increase million compare primarily cost associate acquisition kite primarily consist stockbased compensation transaction cost high bpd fee expense result favorable adjustment million quarter sga expense flat compare decline bpd fee expense offset high cost support new product launch geographic expansion bpd fee expense favorably impact credit million base receipt irs invoice bpd fee expense million million million bpd fee expense tax deductible interest expense interest expense increase billion compare million primarily issuance billion aggregate principal senior unsecured note september note interest expense increase million compare million primarily issuance note billion aggregate principal senior unsecured note issue september income expense net income expense net million million million respectively increase primarily cash cash equivalent marketable security earn high yield high cash balance provision income taxis provision income taxis billion compare billion effective tax rate increase effective tax rate primarily enactment tax reform december change geographic mix earning contribute increase effective tax rate december tax reform sign law united states make significant change internal revenue code amend change include limited corporate tax rate decrease effective tax year begin december implementation modify territorial tax system repatriation tax deem repatriate earning foreign subsidiary calculate provisional estimate impact tax reform income tax provision accordance interpretation tax reform guidance available date filing result record estimate billion net charge income tax expense fourth quarter period tax reform enact include provisional million deferred tax benefit relate remeasurement certain defer tax asset liability base revise rate expect reverse future provisional billion charge relate transition tax mandatory deem repatriation accumulate foreign earning determine december provisional transition tax charge include federal net certain offset adjustment relate unrecognized tax benefit state local foreign withholding tax accumulate foreign earning long consider indefinitely reinveste december accrue federal liability transition tax billion payable year period december million transition tax record accrue liability billion record longterm income taxis payable consolidated balance sheet accordance securities exchange commission sec staff accounting bulletin sab determine million defer tax benefit record connection remeasurement certain defer tax asset liabilitie billion current tax expense record connection transition tax mandatory deem repatriation foreign earning provisional subject adjustment measurement period exceed year enactment tax reform give complexity tax reform refining estimate provisional amount guidance issue treasury sec financial accounting standard board fasb additionally continue evaluate accounting policy election require regard tax global intangible lowtaxed income global minimum tax fasb allow company adopt policy election account global minimum tax method account global minimum tax component tax expense period company subject rule period cost method account global minimum tax company measurement defer taxis defer method elect method completion analysis global minimum tax provision election method depend analyze expect future taxable income inclusion relate global minimum tax methodology order determine appropriate method decide elect defer method account global minimum tax possible provisional estimate remeasure defer taxis materially change finalize analysis accounting policy election measurement period provision income tax billion effective tax rate increase primarily change geographic mix earning liquidity capital resource believe exist capital resource supplement cash flow generate operating activity adequate satisfy capital need foreseeable future follow table summarize cash cash equivalent marketable security work capital million december cash cash equivalent marketable security work capital cash cash equivalent marketable security cash cash equivalent marketable security total billion december increase billion compare billion december generate billion operate cash flow connection acquisition kite issue billion aggregate principal senior unsecured note enter draw billion aggregate principal term loan facility credit agreement billion repay december additionally pay cash dividend billion utilize million stock repurchase note acquisition note consolidated financial statement include item annual report additional detail acquisition kite cash cash equivalent marketable security total billion december increase billion compare billion december generate billion operate cash flow receive billion net proceed note utilize billion repurchase stock repay million principal balance senior note convertible senior note pay cash dividend billion total cash cash equivalent marketable security december approximately billion generate operation foreign jurisdiction february repatriate billion cash cash equivalent marketable security parent company headquarter united states prior enactment tax reform earning consider indefinitely reinveste taxis provide taxis provide earning accrual tax reform transition tax note income taxis note consolidated financial statement include item annual report additional detail tax reform work capital work capital billion december increase billion work capital december primarily drive increase cash cash equivalent shortterm marketable security result shift duration marketable security portfolio reduce interest rate risk partially offset billion increase current portion longterm debt base contractual maturity work capital billion december decrease billion work capital december primarily decline cash cash equivalent result increase longterm marketable security cash flow follow table summarize cash flow activity million cash provide operating activity invest activity financing activity cash provide operating activity cash provide operating activity represent cash receipt disbursement related activity invest financing activity operate cash flow derive adjust net income noncash item change operate asset liability cash provide operating activity decrease billion billion compare primarily low cash receipt result low product sale high tax payment cash provide operating activity decrease billion billion compare primarily low cash receipt result low product sale high cash payment relate accrued government rebate chargeback cash investing activity cash investing activity primarily consist acquisition net cash acquire net purchase marketable security investment capital expenditure cash investing activity increase billion billion compare primarily acquisition kite partially offset low net purchase marketable security cash investing activity decrease million billion compare primarily low net purchase marketable security partially offset investment relate license collaboration agreement galapago cash provide financing activity cash provide financing activity billion compare cash financing activity billion primarily low repurchase common stock high proceed issuance debt partially fund acquisition kite cash financing activity increase billion billion compare primarily high repurchase common stock high net payment debt high payment cash dividend low proceed issuance debt increase partially offset low payment settle warrant relate convertible senior note debt credit facility longterm obligation summary borrowing financing arrangement include note debt credit facility note consolidated financial statement include item annual report senior unsecured note connection acquisition kite issue billion aggregate principal senior unsecured note consist million principal float rate note september million principal float rate note march million principal float rate note september collectively float rate note billion principal senior note september fix rate note collectively float rate note note float rate note bear interest rate equal month london interbank offer rate libor plus respect float rate note september respect float rate note march respect float rate note september fix rate note pay interest semiannually float rate note pay interest quarterly september issue note aggregate principal billion december repay million principal balance relate senior unsecured note require comply certain covenant note indentures december violation covenant term loan facility september enter billion aggregate principal term loan facility credit agreement consist billion principal day senior unsecured term loan facility billion principal threeyear senior unsecured term loan facility billion principal fiveyear senior unsecured term loan facility collectively term loan facility october draw billion aggregate principal term loan facility proceed finance acquisition kite term loan facility bear interest float rate base libor plus applicable margin vary base debt rating fitch rating inc moodys investors service inc global rating day senior unsecured term loan facility threeyear senior unsecured term loan facility payable maturity fiveyear senior unsecured term loan facility payable quarterly amount equal initial principal fiveyear senior unsecured term loan facility fiscal quarter end date second anniversary closing date remain balance payable maturity prepay loan term loan facility time premium penalty amount repay term loan facility reborrowe term loan facility contain customary representation warranty affirmative negative financial maintenance covenant event default december violation covenant repay billion principal balance relate threeyear senior unsecured term loan facility million term loan facility issue credit facility terminate fiveyear billion revolve credit facility enter billion fiveyear revolve credit facility mature fiveyear revolve credit agreement revolve credit facility work capital requirement general corporate purpose include limitation acquisition require comply certain covenant fiveyear revolve credit agreement december violation covenant amount outstanding fiveyear revolve credit agreement capital return program stock repurchase program quarter board director authorize billion stock repurchase program program repurchase open market privately negotiate transaction program commence billion stock repurchase program authorize board director january complete second quarter billion stock repurchase program authorize board director complete quarter december remain authorize repurchase program billion follow table summarize stock repurchase abovedescribe program millions year end december share repurchase retire note repurchase program include million share repurchase billion program million share repurchase billion program include million share repurchase billion program million share repurchase billion program dividend february announce board director declare quarterly cash dividend share common stock payment date march stockholders record close business march future dividend subject declaration board director declare pay quarterly cash dividend aggregate billion common share declare pay quarterly cash dividend aggregate billion common share note stockholder equity note consolidated financial statement include item annual report additional information capital resource believe exist capital resource supplement cash flow generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability possibility acquire additional manufacturing capability office facility possibility acquire company new product debt service requirement establishment additional collaborative relationship company cost associate defense settlement adverse result government investigation litigation include matter relate sofosbuvir future require additional funding form proceed equity debt financing fund require guarantee available favorable term enter collaboration arrangement bristolmyer squibb company bms develop commercialize single tablet regimen contain truvada bmss sustiva efavirenz united states canada combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company consolidate bms grant royaltyfree sublicense joint venture use respective company own technology return grant certain license joint venture use intellectual property result collaboration economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable truvada efavirenz net selling price truvada change time relative net selling price efavirenz bmss respective economic interest joint venture vary annually course collaboration agreement party terminate party participation collaboration day launch generic version party single agent product double agent product terminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination december generic version efavirenz launch united states generic version launch terminate bmss participation collaboration continue party sole owner joint venture december day collaboration result termination transfer gilead bmss ownership interest joint venture consolidate limited liability company whollyowne subsidiary bms long ownership interest joint venture permit commercialize atripla united states canada entitle receive certain royalty net sale atripla calendar year decline annual scale continue purchase efavirenz bm need continue manufacturing atripla united states canada market note collaborative arrangement note consolidated financial statement include item annual report additional information critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement include item annual report prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery occur price fix determinable collectability reasonably assure record product sale net estimate mandatory supplemental discount government payer addition discount private payer relate charge generally refer grosstonet deduction record period relate sale occur government rebate chargeback represent majority grosstonet deduction require complex significant judgment management estimate assess period update reflect current information government rebate chargeback government rebate chargeback include amount pay payer healthcare providers united states include medicaid rebate aid drug assistance program veterans administration public health service discount rebate foreign government rebate rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan qualified program purchase product wholesaler distributor low contractual price wholesaler distributor charge difference acquisition cost low contractual price consolidate allowance government chargeback payable direct customer classify reduction account receivable total million december million december consolidated allowance government rebate pay party direct customer record accrue government rebate consolidated balance sheet total billion december billion december allowance government rebate chargeback estimate base product sell historical utilization rate pertinent thirdparty industry information estimate patient population know market event trend channel inventory datum andor market datum consider new information change program regulation guideline impact actual rebate andor expectation future utilization rate program believe methodology use estimate government rebate chargeback reasonable appropriate give current fact circumstance actual result differ significantly estimate year actual government rebate chargeback claim prior period vary estimate follow table summarize consolidated activity end balance government rebate chargeback account million balance decreaseincrease balance end accrue government rebate chargeback begin year product sale payment year year end december activity relate sale activity relate sale prior total year end december activity relate sale activity relate sale prior total decrease government rebate chargeback compare primarily drive lower hcv sale legal contingency party legal action significant describe note commitment contingency legal proceeding note consolidated financial statement include item annual report possible determine outcome matter recognize accrual action extent conclude loss probable reasonably estimable accrue good estimate loss range estimate range well accrue minimum range determine loss reasonably possible loss range loss estimate disclose possible loss significant judgment require determination probability determination exposure reasonably estimable inherent uncertainty unpredictability relate matter accrual base believe good information available time assessment include legal fact circumstance case status proceeding applicable law view legal counsel final resolution matter possible loss excess record amount material adverse effect result operation cash flow financial position periodically reassess matter additional information available adjust estimate assumption fact circumstance indicate need change recognize accrual matter december believe loss probable valuation intangible asset conjunction business combination record intangible asset primarily relate iprd project total intangible asset billion december compare billion december identifiable intangible asset measure respective fair value acquisition date subject revision measurement period year acquisition date model value intangible asset require use significant estimate assumption include limited estimate revenue operate profit relate product product candidate probability success unapproved product candidate consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market believe fair value record intangible asset acquire connection business combination information know knowable base reasonable estimate assumption give fact circumstance relate valuation date intangible asset relate iprd project consider indefinitelive completion abandonment associate effort development complete generally occur regulatory approval market product obtain associate asset deem finitelived amortize base respective estimate useful life point time period asset consider indefinite live amortize test impairment annual basis annual test aware event change indicate likely fair value iprd project respective carrying amount fair value indefinite live intangible asset dependent assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption change assumption significant impact result operation give period intangible asset finite useful life amortize estimate useful life primarily straightline basis intangible asset finite useful life review impairment fact circumstance suggest carry value asset recoverable october connection kite acquisition acquire intangible asset primarily related iprd axicabtagene ciloleucel kite ktec estimate aggregate fair value billion october fda approve axicabtagene ciloleucel know commercially yescarta make car cell therapy treatment adult patient relapse refractory large bcell lymphoma line systemic therapy include diffuse large bcell lymphoma transform follicular lymphoma primary mediastinal bcell lymphoma approval reclassify billion purchase iprd finitelive intangible asset amortize asset estimate useful life year straightline method note acquisition note consolidated financial statement include item annual report december indefinitelive intangible asset billion consist purchase iprd acquisition kite note acquisition note consolidated financial statement include item annual report estimate fair value iprd relate momelotinib simtuzumab write zero termination clinical development program result record impairment charge million research development expense consolidate statement income include item annual report provision income taxis estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination valuation allowance million december million december increase valuation allowance december december primarily relate kite subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law example united states recently enact significant tax reform certain provision new law significantly affect predict form time potential legislative change material adverse impact result operation addition significant judgment require determine worldwide provision income taxis december tax reform sign law united states make significant change internal revenue code amend change include limited corporate tax rate decrease effective tax year begin december implementation modify territorial tax system repatriation tax deem repatriate earning foreign subsidiary calculate provisional estimate impact tax reform income tax provision accordance interpretation tax reform guidance available date filing result record estimate billion net charge income tax expense fourth quarter period tax reform enact include provisional million deferred tax benefit relate remeasurement certain defer tax asset liability base revise rate expect reverse future provisional billion charge relate transition tax mandatory deem repatriation accumulate foreign earning determine december provisional transition tax charge include federal net certain offset adjustment relate unrecognized tax benefit state local foreign withholding tax accumulate foreign earning long consider indefinitely reinveste december accordance sec sab determine million defer tax benefit record connection remeasurement certain defer tax asset liabilitie billion current tax expense record connection transition tax mandatory deem repatriation foreign earning provisional subject adjustment measurement period exceed year enactment tax reform give complexity tax reform refining estimate provisional amount guidance issue treasury sec fasb additionally continue evaluate accounting policy election require regard tax global intangible lowtaxed income global minimum tax fasb allow company adopt policy election account global minimum tax method account global minimum tax component tax expense period company subject rule period cost method account global minimum tax company measurement defer taxis defer method elect method completion analysis global minimum tax provision election method depend analyze expect future taxable income inclusion relate global minimum tax methodology order determine appropriate method decide elect defer method account global minimum tax possible provisional estimate remeasure defer taxis materially change finalize analysis accounting policy election measurement period record liability relate unrecognized tax benefit accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return adverse resolution uncertain tax position period material impact result operation period total unrecognized tax benefit billion december recognize reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefit decrease approximately million month potential settlement tax examination lapse statute limitation file federal state foreign income tax return unite states foreign jurisdiction federal california income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year income tax return subject audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position note income taxis note consolidated financial statement include item annual report additional information balance sheet arrangement balance sheet arrangement define item aii regulation contractual obligation contractual obligation consist debt obligation operating lease capital commitment purchase obligation active pharmaceutical ingredient inventoryrelate item clinical trial contract follow table summarize significant enforceable legally bind obligation future commitment obligation relate contract likely continue regardless fact certain obligation cancelable december million payment period contractual obligation total year year year year debt operating lease obligation capital commitment purchase obligation clinical trial transition tax payable total note debt primarily consist senior unsecured note term loan facility include principal interest payment interest payment fix rate senior unsecured note incur calculate base term relate note interest payment variable rate debt calculate base interest rate reset date debt instrument note debt credit facility note consolidated financial statement include item annual report additional information amount include firm capital project commitment primarily relate construction new building amount include firm purchase commitment primarily relate active pharmaceutical ingredient certain inventoryrelate item amount include minimum purchase requirement addition commit potential future milestone payment party license collaboration development arrangement payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record consolidated balance sheet include table december clinical study clinical trial phase significant clinical trial expenditure contract research organization cro material contract cro cancelable historically cancel contract amount reflect commitment base exist contract reflect future modification termination exist contract anticipate potential new contract connection tax reform december record federal income tax payable billion transition tax mandatory deem repatriation foreign earning amount include table represent federal income tax payable billion transition tax payable year period amount associate tax reform consider provisional subject adjustment measurement period note income taxis note consolidated financial statement include item annual report additional detail tax reform december longterm income taxis payable include unrecognized tax benefit interest penalty total billion high degree uncertainty time future cash settlement event extinguish unrecognized tax benefit unable estimate period cash settlement exclude unrecognized tax benefit table recent accounting pronouncement information require item include note organization summary significant accounting policy note consolidated financial statement include item annual report item quantitative qualitative disclosure market risk expose market risk result change foreign currency exchange rate interest rate credit risk market price reduce certain risk enter type foreign currency interest rate derivative hedging transaction follow investment guideline monitor outstanding receivables risk management program foreign currency exchange risk operation include manufacture sale activity united states canada ireland sale activity country outside united states include europe asia pacific result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency significant euro dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business approximately product sale denominate foreign currency partially mitigate impact change currency exchange rate net cash flow foreign currency denominate sale enter foreign currency exchange forward option contract hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay general market risk contract offset correspond gain loss transaction hedge december open foreign currency forward contract notional amount billion billion respectively hypothetical adverse movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract hypothetical movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract analysis consider impact hypothetical change foreign currency exchange rate anticipated transaction foreign currency sensitive instrument design offset interest rate risk portfolio availableforsale marketable security fix variable rate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base credit rating maturity industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestgenerate asset interestbeare liability december millions percentage expect maturity total fair total value asset availableforsale debt security average interest rate liability longterm debt include current portion fix rate average interest rate variable rate average interest rate note amount represent principal balance addition fix variable rate longterm debt billion fiveyear revolve credit facility amount outstanding fiveyear revolve credit facility december note debt credit facility note consolidated financial statement include item annual report additional information billion principal fiveyear senior unsecured term loan facility issue october payable quarterly amount equal initial principal fiscal quarter end date start fourth quarter remain balance payable maturity average interest rate variable rate debt base interest rate reset date debt instrument dependent factor subject change include limited libor principal debt outstanding credit rating reset date credit risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe december account receivable net southern europe specifically greece italy portugal spain total approximately million million great day past include million great day past december account receivable net southern europe specifically greece italy portugal spain total approximately million million great day past include million great day past date experience significant loss respect collection account receivable market price risk hold million share common stock galapagos clinicalstage biotechnology company base belgium connection license collaboration agreement enter galapagos equity security classify availableforsale security fair value approximately million million december respectively yearoveryear increase increase common stock price galapago availableforsale equity security subject potential change fair value volatility stock market change general economic condition factor hypothetical decrease stock price investment decrease fair value december approximately million monitor investment temporary decline fair value record impairment loss income temporary decline fair value occur item financial statement supplementary datum gilead sciences inc index consolidated financial statement supplementary data year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement comprehensive income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement select quarterly financial information unaudite schedule valuation qualifying account report independent register public accounting firm stockholder board director gilead sciences inc opinion financial statement audit accompany consolidated balance sheet gilead sciences inc company december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december relate note financial statement schedule list index item collectively refer consolidated financial statement opinion consolidated financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity generally accept accounting principle audit accordance standard public company accounting oversight board united states pcaob companys internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework report date february express unqualified opinion thereon basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion ernst young llp serve company auditor redwood city california february gilead sciences inc consolidated balance sheet million share amount december asset current asset cash cash equivalent shortterm marketable security account receivable net allowance december december inventory prepay current asset total current asset property plant equipment net longterm marketable security intangible asset net goodwill longterm asset total asset liability stockholder equity current liability account payable accrue government rebate accrue liability current portion longterm debt obligation net total current liability longterm debt net longterm income taxis payable longterm obligation commitment contingency note stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize december december share issue outstanding december december additional paidin capital accumulate comprehensive income retain earning total gilead stockholder equity noncontrolle interest total stockholder equity total liability stockholder equity accompany note gilead sciences inc consolidated statement income million share amount year end december revenue product sale royalty contract revenue total revenue cost expense cost good sell research development expense sell general administrative expense total cost expense income operation interest expense income expense net income provision income taxis provision income taxis net income net income loss attributable noncontrolle interest net income attributable gilead net income share attributable gilead common stockholder basic share share calculation basic net income share attributable gilead common stockholder dilute share share calculation dilute cash dividend declare share accompany note gilead sciences inc consolidated statement comprehensive income million year end december net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale security net unrealize gain loss net tax impact respectively reclassification net income net tax impact respectively net change cash flow hedge net unrealized gain loss net tax impact respectively reclassification net income net tax impact respectively net change comprehensive income loss comprehensive income comprehensive income loss attributable noncontrolle interest comprehensive income attributable gilead accompany note gilead sciences inc consolidated statement stockholders equity millions gilead stockholder equity common stock accumulate additional total paidin comprehensive retain noncontrolle stockholder share capital income loss earning interest equity balance december change noncontrolle interest net income loss comprehensive loss net tax issuance employee stock purchase plan issuance equity incentive plans tax benefit employee stock plan stockbase compensation repurchase common stock warrant settlement convertible note settlement convertible note hedge settlement dividend declare reclassification equity component currently redeemable convertible note balance december change noncontrolle interest net income loss comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plans tax benefit employee stock plan stockbase compensation repurchase common stock warrant settlement convertible note settlement convertible note hedge settlement dividend declare reclassification conversion spread convertible note reclassification convertible note hedge reclassification equity component currently redeemable convertible note balance december change noncontrolle interest net income comprehensive loss net tax issuance employee stock purchase plan issuance equity incentive plan stockbase compensation repurchase common stock dividend declare balance december accompany note gilead sciences inc consolidated statement cash flow millions year end december operating activity net income adjustment reconcile net income net cash provide operating activity depreciation expense amortization expense stockbase compensation expense defer income taxis inprocess research development impairment change operate asset liability account receivable net inventory prepaid expense account payable income taxis payable accrue liability net cash provide operating activity invest activity purchase marketable security proceed sale marketable security proceed maturitie marketable security investment acquisition net cash acquire capital expenditure net cash investing activity financing activity proceed debt finance net issuance cost proceed convertible note hedge proceed issuance common stock repurchase common stock repayment debt obligation payment settle warrant payment dividend net cash provide financing activity effect exchange rate change cash cash equivalent net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay net amount capitalize income taxis pay accompany note gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world operation country worldwide headquarters foster city california gileads primary area focus include hivaid liver disease hematologyoncology inflammationrespiratory disease seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy portfolio market product include ambisome atripla biktarvy cayston compleraeviplera descovy emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada tybost vemlidy viread vosevi yescartatm zydelig international commercial sale operation marketing subsidiary country sell distribute certain product corporate partner royaltypaye collaborative agreement basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary certain variable interest entity primary beneficiary intercompany transaction eliminate consolidated entity expose economic record net income loss attributable noncontrolle interest consolidate statement income equal percentage economic ownership interest retain entity respective noncontrolle party assess primary beneficiary variable interest entity vie inception arrangement reporting date assessment base power direct activity vie significantly impact vie economic performance obligation absorb loss right receive benefit vie potentially significant vie december material vie joint venture bristolmyer squibb company bms describe note collaborative arrangement december day joint venture bms united states canada significant accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate significant accounting policy estimate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery occur price fix determinable collectability reasonably assure recognition revenue product sale provision government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product appropriate item deduct gross product sale rebate chargeback estimate reduction revenue amount pay payer healthcare providers united states include medicaid rebate aid drug assistance program veterans administration public health service discount rebate foreign government rebate rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan estimate base product sell historical utilization rate available pertinent thirdparty industry information estimate patient population know market event trend product sale channel inventory datum obtain major wholesaler accordance inventory management agreement consideration available new information change program regulation guideline impact actual rebate andor expectation future utilization rate program government chargeback payable direct customer classify reduction account receivable consolidated balance sheet government rebate invoice directly record accrue government rebate consolidated balance sheet cash discount estimate cash discount base contractual term historical utilization rate expectation future utilization rate distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractually determine covenant maintenance agree inventory level distributor fee base contractually determine fix percentage sale product return provide customer general right product return typically permit return product damage defective receive customer case product sell united states certain country outside united states product expire accept return product expire month expire year expiration date estimate expect return expire product base primarily ongoing analysis historical return pattern historical industry information report return rate similar product contractual agreement intend limit inventory maintain wholesaler royalty revenue royalty revenue sale product generally recognize receive generally quarter follow quarter correspond sale occur month follow month correspond sale occur research development expense research development expense consist primarily personnel cost include salary benefit stockbase compensation clinical study perform contract research organization cro material supply license fee upfront milestone payment collaboration arrangement overhead allocation consist support facilityrelate cost charge cost include clinical study cost expense incur clinical study cost significant component expense clinical study perform thirdparty cro monitor level performance significant contract include extent patient enrollment activity communication cro accrue cost clinical study perform cro service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro material cro contract terminable write notice generally liable actual service complete cro certain noncancelable expense incur point termination sell general administrative expense sell general administrative sga expense relate sale marketing finance human resource legal administrative activity sga expense consist primarily personnel cost facility overhead cost outside marketing advertising legal expense general administrative cost sga expense include brand prescription drug bpd fee expense cost advertising include promotional expense incur advertising expense million million million cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent eligible instrument investment policy include cash equivalent primarily include commercial paper money market fund overnight repurchase agreement major bank authorize dealer bank obligation marketable nonmarketable security marketable debt security determine appropriate classification marketable security time purchase reevaluate designation balance sheet date marketable security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable security longterm marketable security unrealize gain loss availableforsale security exclude net income report accumulate comprehensive income loss aoci separate component stockholder equity income expense net include interest dividend amortization purchase premium discount realize gain loss sale security otherthantemporary decline fair value security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss intent sell security likely require sell security recovery amortize cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carry value security hold record loss decline marketable nonmarketable equity security record investment public company availableforsale security fair market value invest equity security company security publicly trade fair value readily available investment record cost method equity method accounting depend ownership percentage factor indicate significant influence investment record asset unrealize gain loss availableforsale security exclude net income report aoci regularly review security indicator impairment investment nonpublic company material period present concentration risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe japan date experience significant loss respect collection account receivable believe allowance doubtful account adequate december certain raw material component utilize operation obtain single supplier certain raw material utilize operation facility supplier key component raw material name new drug application file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship commercial product supply product candidate clinical trial account receivable trade account receivable record net allowance wholesaler chargeback relate government program cash discount prompt payment doubtful account estimate wholesaler chargeback government program cash discount base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice historically amount uncollectible account receivable write insignificant inventory inventory record low cost net realizable value cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize future commercialization consider probable future economic benefit expect realize base management judgment capitalize prelaunch inventory cost prior regulatory approval number factor take consideration include current status regulatory approval process potential impediment approval process safety efficacy anticipate initiative impact indication compound viability commercialization marketplace trend december prelaunch inventory consolidate balance sheet significant property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straight line method repair maintenance cost expense incur estimate useful life year generally follow description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term office computer equipment include capitalize software unamortize capitalize software cost consolidate balance sheet million december million december capitalize interest construction inprogress include property plant equipment interest capitalize significant acquisition account business combination acquisition method accounting require asset acquire include inprocess research development iprd project liability assume record fair value acquisition date consolidate balance sheet excess purchase price fair value net asset acquire record goodwill determination estimate fair value require significant estimate assumption result record adjustment fair value asset acquire liability assume measurement period year acquisition date correspond offset goodwill transaction cost associate business combination expense incur determine net asset acquire meet definition business combination acquisition method accounting acquire iprd expense goodwill record goodwill intangible asset goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination intangible asset indefinite useful life relate purchase iprd project measure respective fair value acquisition date amortize goodwill intangible asset indefinite useful live intangible asset relate iprd project consider indefinitelive completion abandonment associate effort development complete generally occur regulatory approval market product obtain associate asset deem finitelive amortize base respective estimate useful life point time test goodwill indefinitelive intangible asset impairment annual basis annual test aware event change indicate fair value asset carry amount intangible asset finite useful life amortize estimate useful life primarily straightline basis review impairment fact circumstance suggest carry value asset recoverable impairment longlive asset longlive asset include property plant equipment finitelive intangible asset review impairment fact circumstance internally externally suggest carry value asset asset group recoverable indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset asset group eventual disposition carry asset asset group excess carrying value asset asset group estimate fair value recognize impairment loss foreign currency translation transaction gain loss hedge contract nonus entity operation record functional currency entity result operation nonus dollar functional currency entity translate dollar average currency rate asset liability translate currency rate period end foreign currency translation adjustment record component aoci stockholder equity foreign currency transaction gain loss record income expense net consolidated statement income net foreign currency transaction gain loss immaterial year end december hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract contract positive fair value date default enter derivative contract trading purpose fair value financial instrument apply fair value account financial asset liability nonfinancial asset liability recognize disclose fair value financial statement recur basis define fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine fair value measurement asset liability require record fair value consider principal advantageous market transact marketbase risk measurement assumption market participant use price asset liability risk inherent valuation technique transfer restriction credit risk derivative financial instrument recognize derivative instrument asset liabilitie fair value consolidate balance sheet change fair value derivative record period current earning aoci depend derivative designate hedge transaction type hedge transaction classify cash flow instrument category cash flow hedge item hold issue derivative instrument trade speculative purpose assess inception ongoing basis derivative hedging transaction highly effective offset change cash flow fair value hedge item assess hedge ineffectiveness quarterly basis record gain loss relate ineffective portion current earning extent significant determine forecast transaction probable occur discontinue hedge accounting affect portion hedge instrument relate unrealized gain loss contract recognize income expense net consolidated statement income income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation applicable tax law regulation record liability relate unrecognized tax benefit accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return adverse resolution uncertain tax position period material impact result operation period recently adopt accounting pronouncement november financial accounting standard board fasb issue accounting standard update asu balance sheet classification defer taxis adopt standard retrospective basis quarter asu require defer tax asset liability classify noncurrent balance sheet result consolidate balance sheet december retrospectively adjust result reduction total current asset million increase longterm asset million result reclassification defer tax liability material march fasb issue accounting standard update asu improvement employee sharebase payment accounting adopt standard january aspect standard require excess tax benefit deficiency arise vest exercise share base award recognize income statement prospective basis previous guidance tax effect record additional paidin capital result recognize million excess tax benefit provision income taxis consolidate statement income result impact share calculation dilute earning share material additionally allow standard elect continue estimate potential forfeiture aspect asu amend presentation certain sharebased payment item statement cash flow adopt retrospective basis result consolidated statement cash flow adjust reclassify million million respectively excess tax benefit stockbase compensation net cash financing activity net cash provide operating activity reclassify million million respectively employee taxis pay tax authority withhold share meet minimum statutory withholding requirement change accrue liability net cash provide operating activity net cash financing activity january fasb issue accounting standard update asu clarify definition business asu clarifie definition business evaluate transaction account acquisition disposal asset business anticipate transaction account asset acquisition business acquisition provision new standard adopt standard prospective basis fourth quarter impact adoption material effect consolidated financial statement recently issue accounting pronouncement adopt fasb issue accounting standard update asu revenue contract customer standard core principle report entity recognize revenue transfer promise good service customer reflect consideration entity expect entitled exchange good service standard effective begin quarter early adoption permit entity option retrospective modify retrospective approach adopt new guidance fasb issue supplemental adoption guidance clarification asu march april december asu revenue contract customer principal versus agent consideration asu revenue contract customer identify performance obligation license asu revenue contract customer narrowscope improvement practical expedient asu technical correction improvement topic revenue contract customer respectively adopt standard modify retrospective approach cumulative effect adopt standard record retain earning january complete assessment effect adoption base assessment accelerate recognition royalty revenue certain revenue recognize cash basis sell method period sale occur subject constraint variable consideration expect adoption standard material impact consolidate financial statement january fasb issue accounting standard update asu financial instrument overall recognition measurement financial asset financial liability asu change account equity investment financial liability fair value option presentation disclosure requirement financial instrument addition clarify guidance relate valuation allowance assessment recognize defer tax asset result unrealized loss availableforsale debt security guidance effective begin quarter adopt modify retrospective approach certain exception early adoption permit certain provision plan adopt guidance quarter expect impact primarily relate recognition measurement equity investment galapagos galapagos reclassify unrealized net gain aoci retain earning date adoption primarily comprise million unrealized gain base fair value equity investment galapago december february fasb issue accounting standard update asu lease asu amend number aspect lease accounting include require lessee recognize lease term great year rightofuse asset correspond liability measure present value lease payment guidance effective begin quarter require adopt modify retrospective approach early adoption permit evaluate impact adoption standard anticipate recognition additional asset correspond liability relate lease consolidate balance sheet june fasb issue accounting standard update asu financial instrument credit loss measurement credit loss financial instrument asu require measurement recognition expect credit loss financial asset guidance effective begin quarter adopt modify retrospective approach certain exception early adoption permit begin quarter evaluate impact adoption standard consolidated financial statement fair value measurement determine fair value financial nonfinancial asset liability fair value hierarchy establish level input measure fair value follow level input include quote price active market identical asset liability level input include observable input level input quote price similar asset liability quote price identical similar asset liability market active input observable corroborate observable market datum substantially term asset liability marketable security review trading activity pricing measurement date sufficient quote price identical security available use market pricing observable market input similar security obtain thirdparty datum provider input represent quote price similar asset active market derive observable market datum level input include unobservable input support little market activity significant fair value underlie asset liability level asset liability include fair value measurement determine pricing model discount cash flow methodology similar valuation technique significant management judgment estimation financial instrument consist primarily cash cash equivalent marketable security account receivable foreign currency exchange contract equity security account payable shortterm longterm debt cash cash equivalent marketable security foreign currency exchange contract equity security report respective fair value consolidate balance sheet shortterm longterm debt report amortize cost consolidate balance sheet remain financial instrument report consolidated balance sheet amount approximate current fair value transfer level level level period present follow table summarize type asset liability measure fair value recur basis level fair value hierarchy million december december level level level total level level level total asset corporate debt security certificate deposit money market fund treasury security residential mortgage assetbacke security government agency security nonus government security municipal debt security equity security defer compensation plan foreign currency derivative contract total liability defer compensation plan foreign currency derivative contract contingent consideration total level input estimate fair value level instrument take consideration valuation obtain thirdparty pricing service pricing service utilize industry standard valuation model include income marketbase approach significant input observable directly indirectly estimate fair value input include report trade brokerdealer quote similar security issuer credit spread benchmark security prepaymentdefault projection base historical datum observable input substantially foreign currency derivative contract maturity month time horizon counterpartie minimum credit rating equivalent global rating moodys investors service inc fitch ratings inc estimate fair value contract take consideration valuation obtain thirdparty valuation service utilize incomebase industry standard valuation model significant input observable directly indirectly input include foreign currency exchange rate london interbank offer rate libor swap rate input applicable observable commonly quote interval total estimate fair value shortterm longterm debt determine level input base quote market value approximately billion billion december respectively carry value billion billion december respectively level input december asset liability measure level input recur basis contingent consideration liability immaterial nonrecurre basis measure certain asset include intangible asset fair value carry value asset exceed fair value estimate fair value iprd relate momelotinib simtuzumab write zero termination clinical development program result record impairment charge million policy recognize transfer level classification actual date event change circumstance cause transfer availableforsale security estimate fair value availableforsale security generally base price obtain commercial pricing service follow summarize availableforsale security million december december gross gross gross gross amortize unrealize unrealized estimate amortize unrealize unrealized estimate cost gain loss fair value cost gain loss fair value corporate debt security certificate deposit money market fund treasury security residential mortgage assetbacke security government agency security nonus government security municipal debt security equity security total follow table summarize classification availableforsale security consolidate balance sheet million december december cash cash equivalent shortterm marketable security prepay current asset longterm marketable security longterm asset total cash cash equivalent table exclude cash billion billion december respectively follow table summarize availableforsale security contractual maturity million december amortize cost fair value year year year year year year total follow table summarize availableforsale security continuous unrealized loss position deem otherthan temporarily impair million month month great total gross gross gross unrealize estimate unrealized estimate unrealized estimate loss fair value loss fair value loss fair value december corporate debt security treasury security residential mortgage assetbacke security government agency security nonus government security total december corporate debt security treasury security residential mortgage assetbacke security government agency security nonus government security certificate deposit municipal debt security total hold total position december respectively relate debt security unrealize loss position base review availableforsale security believe otherthantemporary impairment security december intend sell security believe require sell security recovery amortize cost basis gross realize gain gross realize loss immaterial year end december derivative financial instrument operation foreign country expose market risk associate foreign currency exchange rate fluctuation dollar foreign currency primarily euro order manage risk hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract contract positive fair value date default enter derivative contract trading purpose hedge exposure foreign currency exchange rate fluctuation certain monetary asset liability entity denominate non functional currency derivative instrument use hedge exposure designate hedge result change fair value record income expense net consolidated statement income hedge exposure foreign currency exchange rate fluctuation forecast product sale denominate nonfunctional currency derivative instrument use hedge exposure designate cash flow hedge maturity month execute hedge contract quarterly assess prospective hedge effectiveness regression analysis calculate change cash flow result hedge instrument quarterly basis assess retrospective hedge effectiveness dollar offset approach exclude time value effectiveness testing recognize change time value hedge income expense net consolidated statement income effective component hedge record unrealized gain loss hedge instrument aoci stockholder equity consolidated balance sheet gain loss reclassify product sale hedge transaction affect earning majority gain loss relate hedged forecast transaction report aoci december expect reclassify product sale month cash flow effect derivative contract year end december include net cash provide operating activity consolidate statement cash flow notional amount foreign currency exchange contract outstanding billion billion december respectively derivative contract allow right offset asset liability present amount gross basis international swap dealers association inc master agreement respective counterpartie foreign currency exchange contract subject applicable requirement allow net settle transaction currency single net payable party follow table summarize classification fair value derivative instrument consolidate balance sheet million december asset derivative liability derivative fair classification fair value classification value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative december asset derivative liability derivative fair classification fair value classification value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge total derivative follow table summarize effect foreign currency exchange contract consolidate financial statement millions year end december derivative designate hedge gain loss recognize aoci effective portion gain loss reclassify aoci product sale effective portion gain loss recognize income expense net ineffective portion amount exclude effectiveness testing derivative designate hedge gain loss recognize income expense net time time discontinue cash flow hedge result record relate amount income expense net consolidated statement income material amount record income expense net year end december result discontinuance cash flow hedge december hold type financial instrument derivative contract relate foreign currency exchange contract follow table summarize potential effect offset derivative type financial instrument consolidated balance sheet million december offset derivative assetsliabilitie gross amount offset consolidated balance sheet gross amount offset amount assetsliabilitie gross amount consolidated balance present consolidated derivative financial cash collateral net description recognize assetsliabilitie sheet balance sheet instrument receivedpledge legal offset derivative asset derivative liability december offset derivative assetsliabilitie gross amount offset consolidated balance sheet gross amount offset amount assetsliabilitie gross amount consolidated balance present consolidated derivative financial cash collateral net description recognize assetsliabilitie sheet balance sheet instrument receivedpledge legal offset derivative asset derivative liability convertible senior note convertible note hedge march exercise option elect cash settlement conversion value excess principal conversion spread remain convertible senior note convertible note relate convertible note hedge cash settlement election conversion spread convertible note convertible note hedge meet applicable criterion equity classification record stockholder equity consolidated balance sheet cash settlement election reclassify million fair value conversion spread stockholders equity current portion longterm debt obligation net reclassify million fair value convertible note hedge stockholder equity prepay current asset consolidate balance sheet maturity convertible note settle conversion spread convertible note hedge cash million respectively record loss million conversion spread gain million convertible note hedge consolidate statement income acquisition kite pharma inc october acquisition date complete tender offer outstanding common stock kite pharma inc kite share cash result kite whollyowne subsidiary acquisition kite help establish foundation improve treatment hematological malignancy solid tumor kite cell therapy express chimeric antigen receptor car engineer cell receptor depend type cancer kite advanced therapy candidate axicabtagene ciloleucel car cell therapy october axicabtagene ciloleucel know commercially yescarta approve fda make car cell therapy treatment adult patient relapse refractory large bcell lymphoma line systemic therapy include diffuse large bcell lymphoma dlbcl transform follicular lymphoma tfl primary mediastinal bcell lymphoma pmbcl marketing authorization application file axicabtagene ciloleucel treatment relapsedrefractory dlbcl tfl pmbcl european medicine agency kite additional candidate clinical trial hematologic cancer solid tumor include kite car cell therapy candidate target bcell maturation antigen express multiple myeloma consideration transfer acquisition million consist million cash outstanding kite common stockholder million cash payment vested equity award holder million warrant holder approximately million represent portion replace stock base award attributable precombination period addition approximately million exclude consideration transfer represent portion replace stockbased award attributable post combination period million recognize compensation expense month end december remain stockbase compensation expense replacement award expect recognize finance transaction billion aggregate principal senior unsecured note issue september billion aggregate principal term loan facility credit agreement enter september draw october cash hand note debt credit facility additional information acquisition kite account business combination acquisition method accounting method require thing asset acquire liability assume recognize fair value acquisition date fair value estimate asset acquire liability assume base preliminary valuation information know knowable date file able complete valuation obtain additional information primarily relate certain forecast assumption perform preliminary valuation intangible estimate record benefit certain tax attribute change assumption estimate cause impact valuation asset acquire include intangible asset goodwill relate tax impact acquisition follow table summarize preliminary acquisition date fair value asset acquire liability assume consideration transfer millions cash cash equivalent identifiable intangible asset indefinitelive intangible asset iprd outlicense acquire deferred income taxis asset acquire liability assume net total identifiable net asset goodwill total consideration transfer identifiable intangible asset acquire intangible asset primarily related iprd axicabtagene ciloleucel kite ktec estimate aggregate fair value million acquisition date fair value asset determine probabilityweighte income approach discount expect future cash flow present value estimate net cash flow discount discount rate base estimate weightedaverage cost capital company profile similar kite rate comparable estimate internal rate return acquisition represent rate market participant use value intangible asset project cash flow iprd asset base key assumption estimate revenue operate profit relate project consider stage development acquisition date time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive asset completion abandonment associate effort october fda approval yescarta treatment adult patient relapse refractory dlbcl line systemic therapy million purchase iprd reclassify finitelived intangible asset amortize estimate useful life year straight line method additionally acquire outlicense daiichi sankyo estimate fair value million acquisition date definitelive intangible asset amortize estimate useful life year straightline basis fair value determine estimating probability weight net cash flow attributable outlicense discount present value discount rate represent estimate rate market participant use value intangible asset goodwill million goodwill represent excess consideration transfer fair value asset acquire liability assume represent future economic benefit arise asset acquire individually identify separately recognize goodwill deductible income tax purpose actual supplemental pro forma information financial result kite date acquisition include consolidated statement income year end december kite pretax operating loss approximately million include expense million associate acquisition kite kite pretax operating loss include million sharebased compensation expense million accelerate vest compensation charge associate acquisition million acquire iprd expense primarily relate acquisition cell design labs inc cell design lab million amortization intangible asset sharebase compensation expense record primarily research development expense sell general administrative expense acquire iprd expense record research development expense amortization expense record cost good sell consolidated statement income year end december connection acquisition kite incur million transaction cost record sell general administrative expense consolidate statement income year end december follow pro forma information present combine result operation gilead kite acquisition kite complete january adjustment effect pro forma event directly attributable acquisition million unaudite year end december total revenue net income attributable gilead unaudited pro forma consolidated result include pro forma adjustment directly attributable acquisition assume acquisition occur january primary adjustment include compensation expense million acquisitionrelate transaction expense million inclusive kite transaction expense incur include net income attributable gilead year end december impact additional interest expense debt issue connection acquisition kite assume debt incur january unaudite pro forma result reflect operating efficiency potential cost saving result consolidation operation gilead kite accordingly unaudite pro forma result present informational purpose necessarily indicative actual result operation combine company acquisition occur begin indicative future result operation cell design labs inc december acquire issue outstanding stock cell design lab privately hold company addition approximately share cell design lab obtain acquisition kite acquisition gain new technology platform enhance research development effort cellular therapy cash consideration total million net acquire cash additionally shareholder cell design lab eligible receive contingent development regulatory milestonebase payment million equity interest cell design lab carry value million transaction account asset acquisition result million expense acquire iprd research development expense consolidate statement income nimbus apollo inc acquire nimbus apollo inc privately hold company acetylcoa carboxylase inhibitor program evaluate potential treatment nonalcoholic steatohepatitis hepatocellular carcinoma disease consideration include payment million contingent development regulatory milestonebase payment million transaction account asset acquisition result payment million expense acquire iprd research development expense consolidate statement income base achievement certain clinical development milestone record million expense research development expense consolidate statement income inventory inventory summarize follow million december raw material work process finish good total report inventory longterm asset total amount report longterm asset primarily consist raw material december joint venture bms consolidate hold efavirenz active pharmaceutical ingredient inventory efavirenz inventory purchase bms bmss estimate net sell price efavirenz december generic version efavirenz launch united states generic version launch terminate bmss participation collaboration united states canada sole owner joint venture country december day collaboration united states canada result termination pursuant term exist agreement govern collaboration united states canada record million reduction inventory receivable bms adjust purchase price inventory hand termination date remain collaborative arrangement bms continue purchase efavirenz bms bmss estimate net selling price efavirenz note collaborative arrangement additional information december efavirenz inventory value bmss estimate net selling price total million billion respectively property plant equipment property plant equipment summarize follow million december land building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment construction progress subtotal accumulate depreciation amortization total intangible asset goodwill follow table summarize carry intangible asset net million december finitelive intangible asset indefinitelive intangible asset total finitelive intangible asset follow table summarize finitelive intangible asset millions december december gross carry accumulate net carry gross carry accumulate net carrying amortization amortization intangible asset sofosbuvir intangible asset axicabtagene ciloleucel dlbcl intangible asset ranexa total amortization expense relate finitelived intangible asset include primarily cost good sell consolidated statement income total million million million december estimate future amortization expense associate finitelive intangible asset follow millions fiscal year total indefinitelive intangible asset december indefinitelive intangible asset million consist purchase iprd acquisition kite note acquisition additional information estimate fair value iprd relate momelotinib simtuzumab write zero termination clinical development program result record impairment charge million research development expense consolidate statement income goodwill complete acquisition kite october preliminarily attribute million goodwill consolidated balance sheet follow table summarize change carry goodwill million balance december goodwill result acquisition kite balance december financial information accrue liability component accrue liability summarize follow million december income taxis payable compensation employee benefit bpd fee accrue expense total collaborative arrangement enter collaborative arrangement party development commercialization certain product party active participant operating activity collaboration expose significant risk reward depend commercial success activity follow significant collaborative arrangement bristolmyers squibb company north america enter collaboration arrangement bms develop commercialize single tablet regimen contain truvada bmss sustiva efavirenz united states canada combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company consolidate bms grant royaltyfree sublicense joint venture use respective company own technology return grant certain license joint venture use intellectual property result collaboration economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable truvada efavirenz net selling price truvada change time relative net selling price efavirenz bmss respective economic interest joint venture vary annually course collaboration agreement party terminate party participation collaboration day launch generic version party single agent product double agent product terminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination december generic version efavirenz launch united states generic version launch terminate bmss participation collaboration continue party sole owner joint venture december day collaboration result termination transfer gilead bmss ownership interest joint venture consolidate limited liability company whollyowne subsidiary bms long ownership interest joint venture permit commercialize atripla united states canada entitle receive certain royalty net sale atripla calendar year decline annual scale continue purchase efavirenz bm need continue manufacturing atripla united states canada markets transfer bmss ownership interest joint venture account equity transaction reduce associate noncontrolle interest zero reflect derecognition bmss ownership interest difference consideration payable bms noncontrolle interest insignificant record reduction additional paidincapital apic associate cash flow effect transfer bmss ownership interest reflect cash financing activity consolidate statement cash flow year end december settle december joint venture hold efavirenz active pharmaceutical ingredient purchase bms bmss estimate net selling price efavirenz market amount primarily include inventory consolidate balance sheet december select financial information joint venture follow million december total asset cash cash equivalent account receivable net inventory total liability account payable accrue liability asset liability amount reflect impact intercompany elimination include consolidated balance sheet consolidated joint venture legal structure joint venture limited recourse creditor general credit asset similarly asset hold joint venture settle obligation joint venture europe gilead sciences ireland whollyowne subsidiary bms enter collaboration agreement set forth term condition bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bmss estimate net selling price efavirenz european territory responsible manufacturing product distribution inventory management warehouse local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory bms promote atripla general party share revenue outofpocket expense proportion net selling price component atripla truvada efavirenz start limited number activity jointly manage party long coordinate detail promotional activity european territory responsible accounting financial reporting tax reporting collaboration december efavirenz purchase bms bmss estimate net selling price efavirenz european territory include inventory consolidate balance sheet party form limited liability company hold marketing authorization atripla european territory primary responsibility regulatory activity major market country party agree independently continue use commercially reasonable effort promote atripla agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european territory addition december party terminate agreement reason termination effective calendar quarter notice termination nonterminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination event continue party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early japan tobacco inc japan tobacco inc japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize elvitegravir treatment hiv infection bear cost expense associate commercialization effort receive approval stribild elvitegravircontaine product fda august european commission receive approval genvoya elvitegravircontaine product fda european commission november agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party janssen enter license collaboration agreement janssen sciences ireland janssen tibotec pharmaceutical develop commercialize fixeddose combination truvada janssen nonnucleoside reverse transcriptase inhibitor rilpivirine combination approve united states european union sell brand complera united states eviplera european union original agreement janssen grant exclusive license compleraeviplera worldwide exclude certain middle income develop world country japan amend agreement include distribution compleraeviplera rest world amend agreement expand collaboration include product contain janssen rilpivirine emtricitabine tenofovir alafenamide odefsey amend agreement janssen grant exclusive license compleraeviplera odefsey worldwide retain right distribute combination product country include mexico russia japan party restrict combine drug drug product similar component compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization product country janssen distribute janssen exercise right codetail combination product country gilead sell party initial agreement price compleraeviplera expect sum price truvada price rilpivirine purchase separately cost rilpivirine purchase janssen compleraeviplera approximately market price rilpivirine specified percentage major market financial provision amendment effective enable sell party set price combine product party share revenue base ratio net selling price party component subject certain restriction adjustment continue retain specify percentage janssen share revenue major market party terminate collaboration agreement respect product country product withdraw market country respect product country party materially breach agreement respect product agreement party obligation share revenue expire productbyproduct countrybycountry basis janssen patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement cause respect country sell product case janssen right sell party country product launch market few year galapago close license collaboration agreement galapago clinicalstage biotechnology company base belgium development commercialization filgotinib jakselective inhibitor evaluate inflammatory disease indication closing license collaboration agreement upfront license fee payment million million equity investment galapago subscribe new share price share include issuance premium result receive million new share galapago represent outstanding share capital closing license collaboration agreement license fee payment million issuance premium equity investment million record research development expense consolidate statement income equity investment net issuance premium record availableforsale security longterm asset consolidate balance sheet closing license collaboration agreement december december investment record prepay current asset consolidate balance sheet galapago eligible receive development regulatory milestonebase payment million salesbase milestone payment million plus tiere royalty global net sale range exception certain copromotion territory profit shared equally base achievement certain clinical development milestone record million expense research development expense consolidate statement income term agreement exclusive worldwide royaltybearing sublicensable license filgotinib product contain filgotinib primarily responsible development seek regulatory approval relate filgotinib responsible galapago responsible development cost incur responsible manufacturing commercialization activity galapago exercise option promote filgotinib certain territory territory galapago share profit equally debt credit facility follow table summarize carry borrowing financing arrangement million december type borrowing issue date date interest rate senior unsecured september september senior unsecured september september month libor term loan october october variable senior unsecured september march month libor senior unsecured march april term loan variable senior unsecured september september senior unsecured september september month libor senior unsecured november february senior unsecured september september term loan october october variable senior unsecured march april senior unsecured december december senior unsecured september march senior unsecured september september term loan october october variable senior unsecured september september senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march total debt net current portion total longterm debt net senior unsecured note connection acquisition kite issue billion aggregate principal senior unsecured note register offering consist million principal float rate note september million principal float rate note march million principal float rate note september collectively float rate note billion principal senior note september fix rate note collectively float rate note note term summarize table issue billion aggregate principal senior unsecured note note register offering collectively refer note note senior unsecured note issue september note march november notes march december note senior note senior note float rate note redeem option redemption price equal great principal note redeem sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus makewhole premium define indenture senior note mature feature exercisable option redeem note par month immediately precede maturity case accrue unpaid interest require redeem date redemption option redeem series float rate note prior maturity date repay maturity million principal balance relate note event occurrence change control downgrade rate senior note investment grade moodys investors service inc global rating holder require purchase portion note price equal aggregate principal note repurchase plus accrue unpaid interest date repurchase require comply certain covenant senior note december violation covenant recognize billion million million interest expense senior note relate contractual coupon rate amortization debt discount issuance cost term loan facility september enter billion aggregate principal term loan facility credit agreement consist billion principal day senior unsecured term loan facility billion principal threeyear senior unsecured term loan facility billion principal fiveyear senior unsecured term loan facility collectively term loan facility october draw billion principal term loan facility proceed finance acquisition kite term loan facility bear interest float rate base libor plus applicable margin vary base debt rating fitch rating inc moodys investors service inc global rating day senior unsecured term loan facility threeyear senior unsecured term loan facility payable maturity fiveyear senior unsecured term loan facility payable quarterly amount equal initial principal fiveyear senior unsecured term loan facility fiscal quarter end date second anniversary closing date remain balance payable maturity prepay loan term loan facility time premium penalty term loan facility contain customary representation warranty affirmative negative financial maintenance covenant event default december violation covenant repay billion principal balance relate threeyear senior unsecured term loan facility million term loan facility issue cash bridge facility august enter billion principal day senior unsecured term loan facility cash bridge facility cash bridge facility terminate result issuance note enter term loan facility september amount draw cash bridge facility convertible senior note july issue billion convertible note par private placement concurrent issuance convertible note purchase convertible note hedge sell warrant private transaction portion convertible note convert remainder mature repay aggregate principal balance million pay million cash relate conversion spread convertible note represent conversion value excess principal receive million cash convertible note hedge relate convertible note pay million settle warrant average market price common stock exceed warrant exercise price credit facility terminate fiveyear billion revolve credit facility enter billion fiveyear revolve credit facility agreement mature fiveyear revolve credit agreement revolve credit facility work capital requirement general corporate purpose include limitation acquisition december amount outstanding fiveyear revolve credit agreement fiveyear revolve credit agreement contain customary representation warranty affirmative negative covenant event default december violation covenant loan fiveyear revolve credit agreement bear interest eurodollar rate plus applicable percentage base rate plus applicable percentage define fiveyear revolve credit agreement terminate reduce commitment prepay loan fiveyear revolve credit agreement time premium penalty contractual maturity finance obligation december aggregate future principal maturity finance obligation year base contractual date follow millions contractual maturity commitment contingency lease arrangement lease facility equipment relate primarily administrative sale marketing activity longterm noncancelable operating lease united states international market lease expire date lease contain option renew lease expense operating lease million million million aggregate noncancelable future minimum rental payment operating lease follow million total legal proceeding party legal action significant describe recognize accrual action extent conclude loss probable reasonably estimable accrue good estimate loss range estimate range well accrue minimum range determine loss reasonably possible loss range loss estimate disclose possible loss note possible determine outcome matter reasonably estimate maximum potential exposure range possible loss recognize accrual litigation consolidated balance sheet december december believe loss probable litigation relate sofosbuvir january acquire pharmasset inc pharmasset acquisition acquire sofosbuvir nucleotide analog act inhibit replication hepatitis virus hcv december receive approval fda sofosbuvir know commercially sovaldi sofosbuvir include market hcv product receive number contractual intellectual property claim sofosbuvir carefully consider claim prior follow acquisition believe merit predict ultimate outcome claim range loss state aware patent patent application own party future allege party cover use hcv product party obtain valid enforceable patent successfully prove infringement patent hcv product require pay significant monetary damage predict ultimate outcome intellectual property claim relate hcv product spend continue spend significant resource defend claim interference proceeding litigation idenix pharmaceuticals inc idenix universita degli studi cagliari udsg centre national recherche scientifique luniversite montpellier february receive notice patent trademark office uspto declare interference idenix interference patent patent idenixs pende patent application determine invent certain nucleoside compound january uspto patent trial appeal board ptab determine pharmasset idenix invent compound idenix acquire merck inc merck august idenix appeal ptab decision district court district delaware stayed appeal pende outcome appeal interference involve idenixs patent patent describe light decision second idenix interference favor describe believe district court dismiss idenix interference prejudice enter judgment idenix favor december receive request uspto declare interference second idenix interference pende patent application idenixs patent patent include claim direct method treat hcv nucleoside compound march ptab determine pharmasset idenix invent claim method treat hcv idenix appeal decision district court district delaware court appeal federal circuit cafc cafc hear oral argument september affirm ptab decision june november cafc deny idenixs petition rehear idenix file petition united states supreme court file motion dismiss appeal delaware grant idenix appeal dismissal cafc court stay appeal pende decision second idenix interference believe appeal delaware dismissal dismiss light recent decision cafc affirm ptab prior decision second idenix interference idenix entitle patent believe idenix claim involve second idenix interference similar foreign patent claim compound metabolite use thereof invalid result file impeachment action federal court canada invalidate idenix canadian patent patent canadian patent correspond patent idenix assert commercialization sovaldi canada infringe patent canadian patent correspond patent invalid november canadian court hold idenixs patent invalid patent valid idenix appeal decision canadian federal court appeal november july canadian federal appeal court affirm low court decision favor september idenix appeal decision supreme court canada january file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sovaldi australia infringe australian patent correspond patent march australian court revoke idenixs australian patent idenix appeal decision december federal court australia dismiss idenixs appeal january idenix apply special leave appeal high court australia march european patent office epo grant idenix european patent patent correspond patent day patent grant file opposition epo seek revoke patent opposition hearing hold february epo rule favor revoke patent idenix appeal march idenix initiate infringement proceeding united kingdom germany france allege commercialization sovaldi infringe german french counterpart patent trial hold october december high court justice england wale court invalidate challenge claim patent multiple ground idenix appeal november appeal court affirm court decision invalidate idenixs patent april supreme court refuse idenixs application permission appeal march german court dsseldorf determine idenix patent highly likely invalid stay infringement proceeding pende outcome opposition hearing hold epo february idenix appeal decision german court staying proceeding idenixs request french proceeding stay december idenix udsg centre national recherche scientifique luniversit montpellier sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos patent patent june court transfer massachusetts litigation district court district delaware prior trial december idenix commit covenant sue respect claim arise patent relate sofosbuvir withdraw patent trial addition idenix decline litigate patent infringement action trial light appeal pende cafc invent subject matter claim patent january district court stay idenixs infringement claim patent pende outcome appeal second idenix interference idenix successful persuade united states supreme court consider appeal challenge federal circuit june decision favor second idenix interference ask dismissal judgment enter idenix infringement interference claim jury trial hold december remain patent december jury find willfully infringe assert claim patent award idenix billion past damage party file posttrial motion briefing district judge hear oral argument september september judge deny idenixs motion enhance damage attorney fee february judge grant motion argue patent invalid lack enablement grant motion invalidate idenixs patent vacates jurys award billion past damage idenix indicate plan appeal decision cafc believe court decision correctly find matter law patent invalid remain confident merit case appeal believe possibility material adverse outcome matter remote litigation merck august merck contact request pay royalty sale sofosbuvir obtain license patent patent patent patent coown ionis pharmaceuticals inc patent cover compound include relate sofosbuvir file lawsuit august district court northern district california seek declaratory judgment merck patent invalid infringe patent prosecution merck amend patent application attempt cover compound relate sofosbuvir initially march jury determine establish merck patent invalid lack write description lack enablement award merck million damage june court rule favor defense unclean hand determine merck recover damage patent judge determined merck require pay attorney fee exceptional nature case july court issue decision setting attorney fee award merck file notice appeal cafc court decision defense unclean hand award attorney fee appeal issue relate invalidity merck patent cafc hear oral argument february decision defense unclean hand reverse appeal merck patent uphold require pay damage royalty sale sofosbuvircontaine product follow appeal event judge indicate determine royalty necessary conclusion appeal case litigation university minnesota university minnesota university obtain patent patent purport broadly cover nucleosides antiviral anticancer activity august university file lawsuit district court district minnesota allege commercialization sofosbuvircontaine product infringe patent believe patent invalid infringe continue commercialization sofosbuvir october court grant motion transfer case california file petition inter part review uspto allege assert claim invalid anticipation obviousness petition inter part review file initiative medicine access knowledge october receive notice initiative medicine access knowledge imak submit multiple petition request inter parte review ptab allege certain patent associate sofosbuvir invalid novel obvious strongly believe imak petition merit sofosbuvir approve hcv drug kind novel obvious accordingly defend allegation ptab decide initiate inter parte review decision expect year later party appeal ptab decision cafc european patent claim february party file opposition epo request revocation grant european patent cover sofosbuvir expire october epo uphold validity certain claim sofosbuvir patent appeal decision seek restore original claim original oppose party appeal request revocation appeal process year april party file opposition epo request revocation grant european patent relate sofosbuvir expire january party file opposition epo request revocation grant european patent cover tenofovir alafenamide taf expire july epo uphold validity claim taf patent await write decision epo party file opposition appeal decision appeal process year july party file opposition epo request revocation grant european patent relate taf hemifumarate expire march party file opposition epo request revocation grant european patent cover cobicistat expire december epo uphold validity claim cobicistat patent party file opposition appeal decision appeal process year confident strength patent predict ultimate outcome opposition unsuccessful defend opposition patent claim narrowed revoke patent protection sofosbuvir taf cobicistat european union substantially shorten eliminate entirely patent revoke european patent grant covering compound exclusivity base entirely regulatory exclusivity grant european medicine agency sovaldi grant regulatory exclusivity prevent generic sofosbuvir enter european union year follow approval sovaldi january lose patent protection sofosbuvir prior revenue result operation negatively impact year include succeed year exclusivity lose cause stock price decline litigation relate axicabtagene ciloleucel october acquire kite whollyowne subsidiary acquisition acquire axicabtagene ciloleucel car cell therapy october receive approval fda axicabtagene ciloleucel know commercially yescarta patent patent application claim axicabtagene ciloleucel chimeric dna segment party obtain right patent allegedly prevent attempt prevent commercialize axicabtagene ciloleucel require obtain license order commercialize axicabtagene ciloleucel example aware juno therapeutics inc juno exclusively license patent patent issue sloan kettering cancer center september juno sloan kettering cancer center file lawsuit kite district court central district california allege commercialization axicabtagene ciloleucel infringe patent october follow fda approval yescarta juno file second complaint allege axicabtagene ciloleucel infringe patent juno subsequently move dismiss september complaint maintain october complaint august kite file petition inter parte review uspto allege assert claim patent invalid obvious december ptab determine claim patent invalid obviousness february kite file notice appeal cafc appeal currently pende predict ultimate outcome intellectual property claim relate axicabtagene ciloleucel junos patent uphold valid juno successfully prove infringement patent axicabtagene ciloleucel prevent sell yescarta able obtain license patent license available commercially reasonable term litigation relate bictegravir february viiv healthcare company viiv file lawsuit district court delaware allege commercialization bictegravir know commercially biktarvy infringe viiv patent patent issue shinogi ltd glaxosmithkline llc patent compound patent covering viivs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe claim patent extent viivs patent claim interpret cover bictegravir believe claim invalid uspto grant patent cover bictegravir february viiv file lawsuit federal court canada allege activity relate bictegravir product infringe viiv canadian patent patent issue shinogi ltd viiv patent compound patent covering viivs dolutegravir believe bictegravir infringe claim patent extent viivs patent claim interpret cover bictegravir believe claim invalid predict ultimate outcome intellectual property claim relate bictegravir viivs patent uphold valid viiv successfully prove infringement patent bictegravir require pay significant monetary damage litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug sale generic version product early patent expiration significant negative effect revenue result operation seek approval generic version product nce status generic company submit anda fda year brand product approval current legal proceeding significance generic manufacturer include hiv product february receive notice mylan pharmaceuticals inc mylan submit anda fda request permission manufacture market generic version tybost cobicistat notice mylan allege patent cover cobicistat invalid obvious mylan generic product infringe invalid claim march file lawsuit mylan district court district delaware district court northern district west virginia party agree dismiss action west virginia trial delaware stay patent suit cover tybost list orange book stribild genvoya november receive notice mylan submit anda fda request permission manufacture market generic version evotaz atazanavircobicistat challenge validity cobicistat compound patent cite argument ongoing litigation involve tybost december file lawsuit mylan district court northern district west virginia receive notice amneal pharmaceutical llc amneal submit anda fda request permission manufacture market generic version truvada low dosage strength notice amneal allege patent associate emtricitabine invalid unenforceable andor infringe amneal manufacture use sale generic version truvada low dosage strength july file lawsuit amneal district court district delaware infringement patent june receive notice macleod pharmaceuticals ltd macleod submit andas fda request permission manufacture market generic version truvada atripla notice macleod allege patent associate emtricitabine patent associate emtricitabine tenofovir disoproxil fumarate tdf fixeddose combination patent associate emtricitabine tdf efavirenz fixeddose combination invalid unenforceable andor infringe macleod manufacture use sale generic version truvada atripla july file lawsuit macleod district court district delaware infringement patent december reach agreement macleod resolve lawsuit settlement agreement file federal trade commission department justice require law hcv product february receive notice natco pharma limited natco teva pharmaceuticals teva submit anda fda request permission manufacture market generic version sovaldi tevas notice allege patent associate sofosbuvir invalid unenforceable andor infringe tevas manufacture use sale generic version sovaldi natcos notice allege patent associate sofosbuvir invalid unenforceable andor infringe natcos manufacture use sale generic version sovaldi natco challenge patent list orange book sovaldi evaluate notice letter determine step taf litigation january aids healthcare foundation inc ahf file complaint district court northern district california gilead japan tobacco inc japan tobacco international usa emory university emory april ahf amend complaint add janssen johnson johnson inc defendants ahf claim patent nos invalid addition ahf claim gilead independently akros janssen violate federal state antitrust unfair competition law market sale taf offer taf fixeddose combination product elvitegravir cobicistat emtricitabine genvoya fixeddose combination product elvitegravir rilpivirine odefsey fixeddose combination product elvitegravir descovy ahf seek declaratory judgment invalidity patent monetary damage janssen file motion dismiss ahfs claim ahf oppose june hearing hold motion dismiss july judge grant defendant motion dismiss ahfs claim ahf subsequently appeal court decision dismiss challenge validity taf patent appeal hearing hold june await decision government investigation relate litigation june receive subpoena attorney office northern district california request document relate manufacture relate quality distribution practice complera atripla truvada viread emtriva hepsera letairis cooperate government inquiry april department justice inform follow investigation decline intervene false claim act lawsuit file employee april employee serve amend complaint january federal district court issue order grant entirety prejudice motion dismiss amend complaint february plaintiff file second amend complaint june federal district court issue order grant motion dismiss second amend complaint july plaintiff file notice appeal court appeal ninth circuit july threejudge panel ninth circuit reverse remand case district court northern district california october ninth circuit grant motion stay case pende appeal supreme court united states december file petition writ certiorari supreme court expect supreme court decide hear case later year february receive subpoena attorney office district massachusetts request document relate support organization provide financial assistance patient document concern provision financial assistance patient hcv product cooperate inquiry october receive subpoena attorney office district massachusetts request document relate copay coupon program medicaid price report methodology cooperate inquiry september receive voluntary request information attorney office eastern district pennsylvania request information relate reimbursement support offering clinical education program interaction specialty pharmacy sovaldi harvoni cooperate voluntary request october receive subpoena california department insurance alameda county district attorney office request document relate marketing activity reimbursement support offering clinical education program interaction specialty pharmacy cooperate inquiry november health choice advocate llc serve complaint united states district court eastern district texas allege violation false claim act similar state statute marketing activity reimbursement support offering clinical education program sovaldi harvoni lawsuit unseal united states plaintiffstate decline intervene action evaluate step november receive subpoena department health human service request document relate frontlines communities united states focus program cooperate inquiry november receive subpoena attorney office southern district new york request document relate promotional speaker program hiv cooperate inquiry matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation commitment normal course business enter firm purchase commitment primarily relate active pharmaceutical ingredient certain inventory relate item december commitment year approximately million million million million million amount relate active pharmaceutical ingredient represent minimum purchase commitment actual payment purchase relate active pharmaceutical ingredient billion billion billion stockholder equity stock repurchase program quarter board director authorize billion stock repurchase program program repurchase open market privately negotiate transaction program commence billion stock repurchase program authorize board director january program complete second quarter billion stock repurchase program authorize board director program complete quarter repurchase retire million share common stock million open market transaction program december remain authorize repurchase program billion february enter accelerate stock repurchase program asr repurchase billion common stock program upfront payment billion receive million share common stock million share represent approximately total share calculate base common stock closing price share date enter asr april asr settle receive additional million share common stock base average price common stock asr purchase period predetermine discount result average purchase price common stock asr share account asr separate transaction share common stock acquire treasury stock transaction record transaction date forward contract index common stock upfront payment billion account reduction stockholder equity consolidated balance sheet period payment asr meet applicable criterion equity classification account derivative instrument share receive asr retire period receive follow table summarize stock repurchase abovedescribe program millions share datum year end december share repurchase retire average price share note repurchase program include million share repurchase billion program million share repurchase billion program include million share repurchase billion program million share repurchase billion program addition repurchase stock repurchase program repurchase share common stock withhold employee restrict stock award satisfy applicable tax withholding obligation immaterial exclude table use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate apic base estimate average sale price issue share excess amount charge retain earning follow table summarizes reduction common stock apic charge retain earning result stock repurchase millions year end december reduction common stock apic charge retain earning dividend follow table summarize cash dividend declare common stock million share datum dividend share dividend share quarter second quarter quarter fourth quarter total restrict stock performancebase stock unit dividend equivalent right entitle holder dividend equivalent pay vest share underlie unit february announce board director declare quarterly cash dividend share common stock payment date march stockholders record close business march future dividend subject declaration board director prefer stock million share authorize preferred stock issuable series board authorize determine designation power preference right series prefer stock outstanding december accumulate comprehensive income follow table summarize change aoci component net tax million unrealize gain loss unrealize gain foreign currency availableforsale loss translation security cash flow hedge total balance december comprehensive income reclassification amount reclassify accumulated comprehensive income net current period comprehensive income balance december comprehensive income loss reclassification amount reclassify accumulated comprehensive income net current period comprehensive income loss balance december amount reclassify gain loss cash flow hedge record product sale consolidate statement income note derivative financial instrument additional information amount reclassify gain loss availableforsale security record income expense net consolidated statement income employee benefit provide share base compensation form type equitybase award include restrict stock unit rsus performancebase restrict stock unit psus stock option compensation expense recognize consolidated statement income base estimate fair value award grant date estimate fair value rsus base closing price common stock psus estimate fair value base monte carlo valuation methodology stock price date grant stock option award estimate fair value base blackschole option valuation model equity incentive plan stockholder approve adopt gilead sciences inc equity incentive plan amend plan plan broad base incentive plan provide grant equitybase award include stock option restrict stock unit restrict stock award performance award employee director consultant plan authorize issuance total million share common stock maximum number share issue plan increase million share december total million share remain available future grant plan stock option plan provide option grant designate nonqualifie incentive stock option prior january grant nonqualified incentive stock option stock option grant january nonqualified stock option plan employee stock option grant prior generally vest year stock option grant start generally vest year option exercisable period exceed contractual term year date stock option issue grant price fair market value common stock grant date stock option exercise settle common stock plan previously authorize available pool share follow table summarize activity relate information stock option plan option grant present table kite relate replacement award exercise price fair value underlie common stock grant date weight weightedaverage aggregate average remain intrinsic share exercise price contractual term value thousand dollar year million outstanding december grant grantedreplacement award forfeit expire exercise outstanding december exercisable december expect vest net estimate forfeiture december note connection acquisition kite cell design lab replace unvested kite cell design lab stock option stock option option fair value lattice valuation methodology note acquisition additional information aggregate intrinsic value represent value close stock price trading day year excess weightedaverage exercise price multiply number option outstanding exercisable total intrinsic value option exercise million million billion weightedaverage grant date fair value stock option grant share share share december million unrecognized compensation cost relate stock option expect recognize estimate weightedaverage period year performancebase restrict stock unit plan grant psus vest achievement specify market performance goal include achieve total shareholder return compare predetermine peer group achieve revenue target actual number common share ultimately issue calculated multiplying number psus payout percentage range award generally vest committee subcommittee board determine specify market performance goal achieve fair value psu estimate date grant performance objective define grant depend term award fair value date grant determine base monte carlo valuation methodology closing stock price date grant addition grant psus certain employee plan vest award subject achievement specify individual performance goal typically year period fair value award equal closing price common stock grant date follow table summarize activity relate information psus weight average grant date fair value share share thousand dollar outstanding december grant vest forfeited outstanding december note weightedaverage grantdate fair value share exclude share relate grant currently grant date performance objective define weightedaverage grant date fair value psus grant share share share total grant date fair value vest psus million million million total fair value respective vest date million million million recognize stockbased compensation expense million million million related psus december million unrecognized compensation cost relate psus expect recognize estimate weightedaverage period year restrict stock unit grant timebase rsus certain employee annual employee equity compensation review program new hire employee nonemployee members board rsus share awards entitle holder receive freely tradable share common stock vest rsus generally vest year date grant fair value rsu equal closing price common stock grant date follow table summarize rsu activity relate information weight average grant date fair value share share thousand dollar outstanding december grant grantedreplacement award vest forfeited outstanding december note connection acquisition kite replace unvested kite restrict stock unit restrict stock unit estimate fair value date replacement base closing price common stock date note acquisition additional information weightedaverage grant date fair value rsus grant share share share total grant date fair value vest rsus million million million total fair value respective vest date million million million december million unrecognized compensation cost relate unvested rsus expect recognize weightedaverage period year employee stock purchase plan employee stock purchase plan international employee stock purchase plan amend espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair market value common stock offering date purchase date prior espp offer twoyear lookback feature automatic reset feature provide offer period reset new lowerpriced offering offer price new offering period current offering period begin quarter lookback feature espp offering period sixmonth espp purchase settle common stock espps previously authorize available pool share million share issue espp million total million share common stock authorize issuance espp million share available issuance espp december stockbase compensation follow table summarize total stockbased compensation expense include consolidated statement income million year end december cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense net tax capitalize stockbased compensation cost inventory total million million million capitalize stockbased compensation cost remain inventory million december million december million december stockbase compensation recognize expense requisite service period consolidate statement income straightline expense attribution approach reduce estimate forfeiture estimate forfeiture base historical experience valuation assumption fair value option grant plan purchase espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life follow assumption calculate estimate fair value award year end december expect volatility stock option espp expect term year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant calculate single option approach use blend historical volatility imply volatility trade option common stock determine expect volatility expect term stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect term base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout defer compensation maintain retirement saving plan eligible employee defer compensation income tax purpose section internal revenue code gilead science plan certain foreign subsidiary maintain define benefit plan require local regulatory requirement total matching contribution expense gilead science plan define benefit plan million million million maintain deferred compensation plan director key employee defer compensation amount defer participant deposit rabbi trust total asset liability associate defer compensation plan million december million december net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding period dilute net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding dilutive security outstanding period potentially dilutive share common stock result assume exercise outstanding stock option equivalent assume conversion outstanding convertible note assume exercise warrant relate outstanding convertible note determine treasury stock method convertible note associate warrant settled exclude stock option equivalent approximately million million million weightedaverage share common stock outstanding respectively computation dilute net income share attributable gilead common stockholder effect antidilutive follow table show calculation basic diluted net income share attributable gilead common stockholder million share amount year end december net income attributable gilead share share calculation basic effect dilutive security stock option equivalent conversion spread relate convertible note warrant relate convertible note share share calculation dilute net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder dilute segment information operating segment primarily focus discovery development commercialization innovative medicine area unmet medical need result operation report consolidated basis consistent internal management reporting review chief operating decision maker chief executive officer enterprisewide disclosure product sale revenue longlive assets geographic area revenue major customer present product sale product sale consist follow millions year end december antiviral product harvoni genvoya epclusa truvada atripla descovy stribild viread odefsey compleraeviplera sovaldi vosevi antiviral total antiviral product product letairis ranexa ambisome zydelig product total product sale revenue geographic region follow table summarize total revenue external customer collaboration partner geographic region million product sale productrelate contract revenue attribute region base shipto location royalty nonproduct relate contract revenue attribute region base location collaboration partner year end december revenues united states europe country total revenue longlive asset net book value property plant equipment office computer equipment united states billion december billion december billion december corresponding international location million december million december million december individual international location account percent total balance revenue major customer follow table summarize revenue customer individually account total revenue percentage total revenue year end december mckesson corp amerisourcebergen corp cardinal health inc income taxis income provision income taxis consist follow millions year end december domestic foreign total income provision income taxis provision income taxis consist follow millions year end december federal current deferred state current defer foreign current defer provision income taxis december tax cut job act tax reform sign law make significant change internal revenue code amend change include limited corporate tax rate decrease effective tax year begin december implementation modify territorial tax system repatriation tax deem repatriate earning foreign subsidiary calculate provisional estimate impact tax reform income tax provision accordance interpretation tax reform guidance available date filing result record estimate billion net charge income tax expense fourth quarter period tax reform enact include provisional million deferred tax benefit relate remeasurement certain defer tax asset liability base revise rate expect reverse future provisional billion charge relate transition tax mandatory deem repatriation accumulate foreign earning determine december provisional transition tax charge include federal net certain offset adjustment relate unrecognized tax benefit state local foreign withholding tax accumulate foreign earning long consider indefinitely reinveste december accrue federal liability transition tax billion payable year period december million transition tax record accrue liability billion record longterm income taxis payable consolidated balance sheet accordance securities exchange commission sec staff accounting bulletin sab determine million defer tax benefit record connection remeasurement certain defer tax asset liabilitie billion current tax expense record connection transition tax mandatory deem repatriation foreign earning provisional subject adjustment measurement period exceed year enactment tax reform give complexity tax reform refining estimate provisional amount guidance issue treasury sec fasb february repatriate billion cash cash equivalent marketable security parent company headquarter united states prior enactment tax reform earning consider indefinitely reinveste taxis provide taxis provide earning accrual tax reform transition tax additionally continue evaluate accounting policy election require regard tax global intangible lowtaxed income global minimum tax fasb allow company adopt policy election account global minimum tax method account global minimum tax component tax expense period company subject rule period cost method account global minimum tax company measurement defer taxis defer method elect method completion analysis global minimum tax provision election method depend analyze expect future taxable income inclusion relate global minimum tax methodology order determine appropriate method decide elect defer method account global minimum tax possible provisional estimate remeasure defer taxis materially change finalize analysis accounting policy election measurement period reconciliation federal statutory tax rate apply income taxis effective tax rate summarize follow year end december federal statutory rate state taxis net federal benefit foreign earning different rate research credit transition tax defer tax revaluation effective tax rate defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow million december defer tax asset net operating loss carryforward stockbase compensation reserve accrual currently deductible defer revenue depreciation relate research credit carryforward net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability intangible total defer tax liability net defer tax asset liability valuation allowance million december million december million december increase valuation allowance december december primarily relate kite december federal net operating loss carryforward approximately billion federal net operating loss carryforward start expire utilize federal tax credit carryforward approximately million start expire utilize addition state net operating loss tax credit carryforward approximately million million respectively state net operating loss tax credit carryforward start expire utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization file federal state foreign income tax return unite states foreign jurisdiction federal california income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year income tax return subject audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position total unrecognized tax benefit billion december recognize reduce effective tax rate period recognition continue classify interest penalty relate unrecognized tax benefit income tax provision consolidate statement income accrue interest penalty relate unrecognized tax benefit million december million december december believe reasonably possible unrecognized tax benefit decrease approximately million month potential settlement tax examination lapse statute limitation follow rollforward total gross unrecognized tax benefit millions december balance beginning period tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance end period select quarterly financial information unaudite follow amount million share amount quarter quarter quarter quarter total revenue gross profit product sale net income loss net income loss attributable gilead net income loss share attributable gilead common stockholder basic net income loss share attributable gilead common stockholder dilute total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder dilute note december record estimate billion net charge relate enactment tax cut job act note income taxis note consolidated financial statement include item annual report additional detail gilead sciences inc schedule valuation qualifying account million balance begin additionscharged balance end period expense deduction period year end december account receivable allowance sale return allowance valuation allowance defer tax asset year end december account receivable allowance sale return allowance valuation allowance defer tax asset year end december account receivable allowance sale return allowance valuation allowance defer tax asset note allowance doubtful account cash discount chargeback valuation allowance defer tax asset include million million million december respectively relate acquisition item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness disclosure control procedure define rule securities exchange act amended exchange act control procedure company design ensure information require disclose company report file submit exchange act record process summarize report time period specify security exchange commission rule form information accumulate communicate company management include chief executive officer chief financial officer appropriate allow timely decision require disclosure base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective december management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule exchange act internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include item annual report issue report internal control financial reporting december report audit internal control financial reporting appear change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting report independent register public accounting firm stockholder board director gilead sciences inc opinion internal control financial reporting audit gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework coso criterion opinion gilead sciences inc company maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states pcaob consolidate balance sheet company december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december relate note financial statement schedule list index item report date february express unqualified opinion thereon basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate ernst young llp redwood city california february item information applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file securities exchange commission pursuant regulation connection annual meeting stockholder proxy statement heading nominee board structure executive officer section beneficial ownership reporting compliance write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwgileadcom investor section corporate governance change waiver code ethic disclose website intend satisfy disclosure requirement item form amendment waiver provision code ethic disclose information website item executive compensation information require item incorporate reference section proxy statement heading executive compensation committee board director compensation committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement heading security ownership certain beneficial owner management security authorize issuance equity compensation plan item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading gilead board director board process item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service item